On this page
Quick Reference
Overview and Recommendations
Background
- •Pancreatic ductal adenocarcinoma (PDAC) is a malignant epithelial neoplasm arising from the exocrine pancreas, defined by gland-forming cells in a dense desmoplastic stroma, and accounts for over 90% of all pancreatic cancers. It is the fourth leading cause of cancer death in the United States and the seventh worldwide, with a mortality rate nearly equal its incidence, a reflection of its aggressive biology, late presentation, and limited treatment response.
- •In 2025, an estimated 50,550 deaths from pancreatic cancer are expected in the European Union, with age-standardized mortality rates of approximately 8-9 per 100,000 men and 5-6 per 100,000 women. The disease accounts for 3% of all new cancer cases but 8% of all cancer deaths globally. By 2030, PDAC is projected to become the second leading cause of cancer-related death in the United States, surpassing breast and colorectal cancers.
- •Five-year overall survival for all stages remains under 10%, though for localized, resectable disease it rises to 25-30% with modern adjuvant therapy. The mortality-to-incidence ratio approaches 1:1 because 50-60% of patients present with metastatic disease, 25-30% with locally advanced disease, and only 10-15% with resectable disease at diagnosis.
- •The central pathophysiology involves recurrent somatic mutations in four canonical genes: KRAS (mutated in >90% of cases), TP53 (~70%), CDKN2A (~95% inactivated), and SMAD4 (~55%). These alterations drive constitutive MAPK/PI3K signaling, disable cell-cycle checkpoints, disrupt TGF-β signaling, and promote invasion and metastasis. Transcriptomic profiling defines two consensus molecular subtypes, classical (GATA6-high, better prognosis) and basal-like (GATA6-low, worse prognosis), which stratify prognosis and chemotherapy response.
- •Ischemic etiology dominates in the sense of hereditary predisposition: germline mutations in BRCA1/2, PALB2, ATM, CDKN2A, STK11, and Lynch syndrome genes account for 5-10% of cases. Familial pancreatic cancer (≥2 first-degree relatives) confers a 9- to 18-fold increased risk. Modifiable risk factors include cigarette smoking (25% of cases, RR ~2.0), obesity (BMI ≥30 kg/m², RR 1.2-1.4), new-onset diabetes after age 50 (a sentinel marker), heavy alcohol consumption, and chronic pancreatitis.
- •The paradigm shift in management over the past two decades has been the move from gemcitabine monotherapy to multiagent chemotherapy (FOLFIRINOX, gemcitabine/nab-paclitaxel, NALIRIFOX) for advanced disease, and the recognition of molecular subtypes and actionable alterations (BRCA, MSI-H, KRAS G12C, NRG1 fusions) that enable targeted therapy and immunotherapy in a subset of patients.
Evaluation
- •Suspect pancreatic cancer in any patient with painless jaundice, epigastric pain radiating to the back (especially when supine), unexplained weight loss >10% over 6 months, new-onset diabetes in a non-obese patient over 50 without family history, or acute pancreatitis without gallstones or alcohol use.
- •Ask about symptom duration and progression: painless jaundice with pruritus, dark urine, and pale stools suggests head-of-pancreas tumor; epigastric/back pain, anorexia, early satiety, and fatigue suggest body/tail tumor. Also assess for steatorrhea (fatty stools), nausea, vomiting, and depression (reported in 30-50% of patients, may be the earliest manifestation).
- •Examine for jaundice and scleral icterus, Courvoisier's sign (palpable, non-tender gallbladder in a jaundiced patient, positive predictive value >90% for malignant bile duct obstruction), epigastric mass, ascites (indicates peritoneal carcinomatosis, median survival ~2.5 months), Virchow's node (left supraclavicular lymphadenopathy), and Trousseau's sign (migratory superficial thrombophlebitis). Cachexia with muscle wasting is evident in most patients at presentation.
- •Order a dedicated pancreas protocol CT (triple-phase: noncontrast, arterial, portal venous) with thin slices ≤3 mm and multiplanar reformats for initial diagnosis and staging. This assesses the primary tumor, arterial involvement (celiac axis, SMA, hepatic artery), venous involvement (portal vein, SMV), and distant metastases. Sensitivity >90% for tumors ≥2 cm.
- •If CT is equivocal for liver metastases or vascular involvement, add MRI with MRCP, it detects occult liver lesions in 10-15% of patients initially deemed resectable on CT. MRCP delineates ductal anatomy; main pancreatic duct dilation ≥5 mm with stenosis raises suspicion for malignancy.
- •Perform EUS-guided fine-needle aspiration (EUS-FNA) or fine-needle biopsy (EUS-FNB) with rapid on-site evaluation (ROSE) for tissue diagnosis. Sensitivity is 85-90%, specificity >95%. The same biopsy specimen should be used for histologic confirmation (IHC: CK7+, CK19+, MUC1+; loss of SMAD4 expression in ~55%; aberrant p53 in ~70%) and molecular profiling (KRAS mutation, MMR/MSI status, BRCA1/2).
- •For cystic lesions, perform EUS-FNA with cyst fluid analysis: CEA >192 ng/mL distinguishes mucinous from non-mucinous cysts with ~80% accuracy. Cyst fluid glucose <50 mg/dL and amylase levels further refine classification. When cytology is equivocal, consider EUS-through-the-needle biopsy (EUS-TTNB).
- •Order serum CA 19-9 at baseline and serially during therapy for monitoring treatment response and detecting recurrence. Note: CA 19-9 is neither sensitive nor specific for screening; it is elevated in benign jaundice, pancreatitis, and 5-10% of the population are Lewis antigen-negative (FUT3-null) and cannot synthesize CA 19-9. For these patients, DUPAN-2 can serve as an alternative.
- •Assess performance status using the ECOG scale (0-1 for fit patients, ≥2 for frail) to guide chemotherapy intensity. Evaluate comorbidity burden: pre-existing neuropathy (risk of oxaliplatin worsening), cardiac disease (risk of fluorouracil-induced ischemia), renal function (eGFR for S-1 dosing), and hepatic function (for irinotecan metabolism).
- •Diagnostic criteria for resectability (per NCCN): no arterial contact (celiac axis, SMA, or hepatic artery); ≤180° contact with SMV/PV without vein contour irregularity. Borderline resectable: ≤180° SMA or celiac contact, >180° SMV/PV contact but reconstructable. Locally advanced (unresectable): >180° SMA or celiac contact, unreconstructable SMV/PV. Metastatic: distant organ or peritoneal spread.
- •Also consider staging laparoscopy in patients with borderline resectable or locally advanced disease, or those with resectable disease and high-risk features (CA 19-9 >1000 U/mL, large tumors), it detects occult peritoneal or liver metastases in 10-20% of patients who appear resectable on CT.
- •In patients with inadequate tissue for NGS, consider liquid biopsy (ctDNA targeting KRAS mutations) for molecular profiling. ctDNA detection postoperatively is a strong predictor of recurrence.
- •For high-risk individuals (germline mutation carriers, familial pancreatic cancer with ≥2 affected first-degree relatives), begin screening at age 50 (or 10 years younger than the earliest family diagnosis) with annual EUS and/or MRI/MRCP. Population-based screening is not recommended.
Management
- •For resectable PDAC (stage I-II, no arterial involvement, ≤180° venous contact), perform upfront surgical resection (pancreaticoduodenectomy for head tumors, distal pancreatectomy for body/tail) followed by adjuvant chemotherapy. Initiate mFOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², fluorouracil 2400 mg/m² over 46 hours) every 2 weeks for 12 cycles, this is the preferred regimen based on PRODIGE 24 (5-year OS 43.2% vs 31.4% with gemcitabine, HR 0.64, NNT = 8).
- •If mFOLFIRINOX is contraindicated (poor PS, neuropathy, or other intolerance), use gemcitabine 1000 mg/m² IV days 1, 8, 15 plus capecitabine 830 mg/m² PO BID days 1-21 of a 28-day cycle for 6 cycles (ESPAC-4 regimen), or gemcitabine alone 1000 mg/m² IV weekly for 3 of 4 weeks for 6 cycles.
- •For borderline resectable PDAC (≤180° SMA/celiac contact, >180° SMV/PV but reconstructable), administer neoadjuvant chemotherapy for 2-6 cycles. Options: FOLFIRINOX (same doses as above) or gemcitabine 1000 mg/m² plus nab-paclitaxel 125 mg/m² on days 1, 8, 15 of a 28-day cycle. Restage with CT after each 2-3 cycles; if the tumor becomes resectable, proceed to surgery. The PREOPANC trial showed median OS 17.1 months with neoadjuvant gemcitabine-based chemoradiotherapy vs 13.7 months with upfront surgery (HR 0.73, NNT = 9).
- •For locally advanced unresectable PDAC (>180° SMA/celiac contact, unreconstructable vein), initiate induction chemotherapy. Use FOLFIRINOX (preferred) for 3-6 months, or gemcitabine/nab-paclitaxel if FOLFIRINOX not tolerated. PRODIGE 29 showed median PFS 15.0 vs 7.5 months (HR 0.57) for FOLFIRINOX vs gemcitabine. After 3-6 months, if no progression and good PS, consider chemoradiotherapy or stereotactic body radiotherapy (SBRT) for local control or conversion to resectability.
- •For metastatic PDAC (stage IV), first-line therapy depends on PS. For ECOG PS 0-1, options include: (a) FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², 5-FU 400 mg/m² bolus then 2400 mg/m² over 46 hours) every 2 weeks, median OS 11.1 vs 6.8 months (HR 0.57, NNT = 4); (b) gemcitabine 1000 mg/m² plus nab-paclitaxel 125 mg/m² on days 1, 8, 15 every 28 days, median OS 8.7 vs 6.6 months (HR 0.72, NNT = 5); (c) NALIRIFOX (nanoliposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², 5-FU 2400 mg/m²) every 2 weeks, ESMO 2025 update as new first-line option based on NAPOLI 3 (median OS 11.1 vs 9.2 months, HR 0.83, NNT = 12).
- •For frail patients (ECOG PS ≥2) with metastatic disease, gemcitabine alone 1000 mg/m² weekly for 3 of 4 weeks is reasonable, or best supportive care with symptom management.
- •In patients with germline BRCA1/2 mutations and metastatic PDAC, after at least 16 weeks of platinum-based chemotherapy without progression, initiate maintenance olaparib 300 mg PO BID. POLO trial showed PFS HR 0.53 (NNT = 4 to prevent progression); final OS showed numerical benefit but not statistically significant.
- •For MSI-H/dMMR tumors (≈1-2% of PDAC), use pembrolizumab 200 mg IV every 3 weeks (or 400 mg every 6 weeks) regardless of line of therapy, FDA-approved based on tumor-agnostic indication.
- •For KRAS G12C-mutated PDAC (≈1-2%), consider sotorasib 960 mg PO daily or adagrasib 600 mg PO BID. Objective response rate ~21% in CodeBreaK100. RAS(ON) multiselective inhibitors (daraxonrasib) and KRAS G12D inhibitors (MRTX1133) are under investigation.
- •For NRG1 fusion-positive tumors (e.g., ATP1B1-NRG1), use zenocutuzumab 750 mg IV every 2 weeks, overall response rate 40% in fusion-positive pancreatic cancer.
- •Second-line therapy after first-line FOLFIRINOX or gemcitabine/nab-paclitaxel: liposomal irinotecan 70 mg/m² (or 50 mg/m² if UGT1A1*28 homozygote) plus 5-FU 2400 mg/m² over 46 hours and leucovorin every 2 weeks (NAPOLI-1 regimen), or OFF regimen (oxaliplatin 85 mg/m², folinic acid 200 mg/m², 5-FU 2000 mg/m² over 24 hours) weekly for 4 of 6 weeks.
- •Monitor CA 19-9 every 2-3 cycles during therapy. A decline ≥50% after 2 cycles is associated with longer survival; a rise should prompt restaging for progression. Obtain restaging CT every 2-3 months or sooner for clinical progression.
- •Monitor for chemotherapy toxicities: FOLFIRINOX, myelosuppression (G-CSF prophylaxis for febrile neutropenia risk), diarrhea (loperamide, early irinotecan dose hold), neuropathy (oxaliplatin, dose reduction or switch), fatigue, nausea. Gemcitabine/nab-paclitaxel, myelosuppression, neuropathy (nab-paclitaxel), rash, fatigue. NALIRIFOX, diarrhea, fatigue, nausea, myelosuppression.
- •Provide prophylactic G-CSF (filgrastim 5 μg/kg/day or pegfilgrastim 6 mg once per cycle) for patients on FOLFIRINOX or during dose-dense therapy to reduce febrile neutropenia risk.
- •Initiate pancreatic enzyme replacement therapy (PERT) with meals: lipase 40,000-80,000 units per meal, 20,000-40,000 units per snack, titrated to steatorrhea control. Also manage exocrine insufficiency and malnutrition with dietitian referral.
- •Manage biliary obstruction with and biliary stent placement (plastic or metal). For duodenal obstruction, consider enteral stent or gastrojejunostomy. For refractory pain, consider celiac plexus block or radiosurgery (single fraction 25 Gy).
- •Provide venous thromboembolism prophylaxis with LMWH (enoxaparin 40 mg SC daily) or DOAC (rivaroxaban 20 mg PO daily) in all ambulatory patients receiving chemotherapy, per ITAC-CME guidelines.
- •What NOT to do: Do not use erlotinib as first-line therapy (marginal benefit, HR 0.82, NNT = 20). Do not use non-dihydropyridine CCBs (diltiazem, verapamil), they exacerbate symptoms. Do not delay or omit adjuvant chemotherapy in fit resectable patients. Do not use routine staging laparoscopy in all resectable patients (low yield).
- •When to refer: Refer to a high-volume pancreatic surgery center for any potentially resectable disease. Refer to medical oncology for chemotherapy decision-making and molecular testing. Refer to radiation oncology for locally advanced disease if considering CRT/SBRT. Refer to palliative care early for symptom management, pain control, and psychosocial support. Refer to clinical genetics for germline testing interpretation and family counseling.
- •Discharge criteria (after pancreatectomy): tolerating oral intake, pain controlled on oral analgesics, passing flatus, no fever or signs of pancreatic leak (drain amylase <3x serum amylase), drain output ≤50 mL/day, able to ambulate. For patients on chemotherapy: no febrile neutropenia, controlled nausea/vomiting, adequate oral hydration, and home support.
Board Review — High Yield
- •Painless jaundice + Courvoisier's sign, Palpable, non-tender gallbladder in a jaundiced patient is highly specific for malignant distal bile duct obstruction, typically from pancreatic head cancer.
- •New-onset diabetes in a thin older adult, This is often a paraneoplastic harbinger of pancreatic cancer, especially if accompanied by weight loss or unexplained epigastric pain.
- •KRAS mutation (G12D, G12V, G12R) in >90% of PDAC, Constitutive MAPK/PI3K activation; G12R is paradoxically node-sparing and associated with better prognosis compared to G12D.
- •mFOLFIRINOX as preferred adjuvant therapy, PRODIGE 24 trial: 5-year OS 43.2% vs 31.4% with gemcitabine (HR 0.64). Start within 12 weeks of surgery.
- •NCCN Resectability Classification, Determines treatment: Resectable (upfront surgery + adjuvant chemo); Borderline (neoadjuvant chemo); Locally Advanced (induction chemo ± CRT); Metastatic (palliative chemo).
- •CA 19-9 is for monitoring, not screening, Cannot synthesize if Lewis antigen-negative (5-10% of population). Declines ≥50% after 2 cycles predict better survival.
- •Germline BRCA1/2 testing for all PDAC patients, Enables maintenance olaparib after platinum-based therapy. POLO trial: PFS HR 0.53.
- •Classical vs basal-like molecular subtype, Classical (GATA6-high) has better prognosis (median OS 24.8 vs 13.7 months) and greater sensitivity to FOLFIRINOX.
- •Trousseau's sign (migratory thrombophlebitis), A classic but rare paraneoplastic presentation; VTE at diagnosis independently predicts worse survival (HR 1.62).
- •Pancreatic cancer screening reserved for high-risk individuals, Annual EUS/MRI for germline mutation carriers or families with ≥2 affected first-degree relatives. Population screening is not recommended (USPSTF D rating).
Deep Dive — Evidence Details
Definition and Epidemiology
- ▸Pancreatic ductal adenocarcinoma (PDAC) is the most lethal gastrointestinal malignancy, with a mortality rate nearly equal to its incidence and 5-year overall survival <10% for all stages [2, 40].
- ▸Incidence is rising globally, driven by obesity, diabetes, and aging populations; it is projected to become the second leading cause of US cancer death by 2030 [40, 47, 78].
- ▸Only 10-15% of patients present with resectable disease at diagnosis, underscoring the critical need for early detection strategies [2, 35].
Pancreatic ductal adenocarcinoma (PDAC) is a malignant epithelial neoplasm arising from the exocrine pancreas, defined by gland-forming cells with desmoplastic stroma, and accounts for over 90% of all pancreatic cancers [2]D5[41]D5.
Also Called / Synonyms
- Pancreatic ductal adenocarcinoma (PDAC)
- Pancreatic exocrine carcinoma
- Historical terms: "pancreatic cancer" (used colloquially for PDAC), ductal carcinoma of the pancreas
Clinical Significance
PDAC is the fourth leading cause of cancer death in the United States and the seventh worldwide, with a mortality rate nearly equal its incidence, a reflection of its aggressive biology, late presentation, and limited treatment response [2]D5[40]D5[73]B2b. In 2025, an estimated 50,550 deaths are expected in the EU, with age-standardized mortality rates of approximately 8-9 per 100,000 men and 5-6 per 100,000 women [48]B2c[49]B2c[50]B2c. The disease accounts for 3% of all new cancer cases but 8% of all cancer deaths globally [40]D5[60]B2c. Five-year overall survival for all stages remains under 10%, though for localized, resectable disease it rises to 25-30% with modern adjuvant therapy [13]A1b[40]D5.
Incidence Trends
- Rising incidence: Age-standardized incidence rates have increased 0.5-1% per year in North America and Europe over the past two decades, and steeper increases (2-3% annually) are observed in urban China, attributed to westernized dietary patterns and rising obesity [60]B2c[78]B2b.
- Age: Peak incidence occurs between ages 65 and 75 years; median age at diagnosis is 71 years in the US [2]D5[40]D5.
- Gender: Slight male predominance (male-to-female ratio ≈1.3:1) [2]D5[40]D5.
- Race/ethnicity: In the US, incidence is 50-60% higher in Black individuals compared with White individuals, a disparity linked to differences in diabetes prevalence, smoking, and access to care [30]B2c[77]B2b.
- Geographic variation: Highest rates in North America, Europe, and Australia; lower in Africa and parts of Asia, though rates in Japan and urban China are rising rapidly [48]B2c[60]B2c.
Mortality Trends
- Mortality closely mirrors incidence: 5-year relative survival is 9-10% for all stages combined, improving only marginally from 5-6% in the 1990s [2]D5[40]D5[73]B2b.
- In the European Union, predicted pancreatic cancer deaths for 2025 are 50,550 in men and 44,300 in women [48]B2c. For 2026, the projection is 1,230,000 total cancer deaths EU-wide, with pancreatic cancer remaining among the top five lethal sites [49]B2c.
- Disease stage at diagnosis: 50-60% of patients present with metastatic disease, 25-30% with locally advanced, and only 10-15% with resectable disease at diagnosis [2]D5[35]D5.
- By 2030, PDAC is projected to become the second leading cause of cancer-related death in the United States, surpassing breast and colorectal cancers [40]D5[47]D5.
Risk modifiers contributing to incidence trends
- Obesity: A body mass index (BMI) ≥30 kg/m² increases risk by 20-40%; central adiposity (waist circumference) is an independent predictor [21]B2a[76]B2b.
- Diabetes: New-onset diabetes after age 50 is a sentinel marker, conferring a 2- to 3-fold increased risk of developing PDAC within 3 years [44]D5[76]B2b.
- Smoking: Accounts for 20-25% of all PDAC cases; current smokers have a 2-fold higher risk, which declines after cessation but never fully returns to baseline [78]B2b.
- Alcohol: Heavy consumption (≥30 g/day men; ≥16 g/day women) increases risk in young-onset disease (age 20-39) [18]B2b.
- Inherited predisposition: Germline mutations in BRCA1/2, PALB2, ATM, and account for 5-10% of cases; familial pancreatic cancer (≥2 first-degree relatives) confers a 9- to 18-fold increased risk [55]B2b[59]C4[73]B2b.
Classification of disease stages (for context in this article)
| Stage | Definition (per 8th ed.) | Key feature |
|---|---|---|
| Resectable | No arterial contact, ≤180° venous contact | R0 resection is feasible upfront |
| Borderline resectable | ≤180° SMA or CA contact, >180° SMV/PV but reconstructable | Neoadjuvant therapy is standard |
| Locally advanced (unresectable) | >180° SMA or CA contact, unreconstructable vein | Chemo/RT, never resectable |
| Metastatic | Distant organ or peritoneal spread | Incurable; systemic therapy only |
| (Sources: NCCN [24]C4, ESMO [41]D5) |
Pearl: Pancreatic ductal adenocarcinoma is the most lethal common cancer, with a mortality-to-incidence ratio approaching 1:1 and a rising incidence projected to make it the second leading cause of US cancer death by 2030 [40]D5[47]D5. The only chance for long-term survival is detection at a resectable stage, yet 80-90% of patients present with unresectable or metastatic disease at diagnosis [2]D5[35]D5.
| Stage | Definition (per AJCC 8th ed.) | Key feature |
|---|---|---|
| Resectable | No arterial contact, ≤180° venous contact | R0 resection feasible upfront |
| Borderline resectable | ≤180° SMA or CA contact, >180° SMV/PV but reconstructable | Neoadjuvant therapy is standard |
| Locally advanced (unresectable) | >180° SMA or CA contact, unreconstructable vein | Chemo/RT, never resectable |
| Metastatic | Distant organ or peritoneal spread | Incurable; systemic therapy only |
| (Sources: NCCN [24]C4, ESMO [41]D5) |
Risk Factors and Prevention
- ▸Cigarette smoking is the strongest modifiable risk factor, causing about 25% of cases and conferring a ~2-fold risk that persists for 15-20 years after cessation [150, 96].
- ▸Only high-risk individuals (familial/germline predisposition) are candidates for pancreatic cancer screening with annual EUS or MRI/MRCP; population screening is not recommended [92, 94, 73].
- ▸A new diagnosis of diabetes in a non-obese adult >50 years is a potential paraneoplastic signal for pancreatic cancer and should prompt further evaluation [42, 44].
The risk of is shaped by a constellation of non-modifiable genetic factors and modifiable environmental exposures, with cigarette smoking accounting for approximately 25% of all cases and conferring a roughly two-fold increase (RR 2.0) that persists for over a decade after cessation [150]D5. Understanding these risk factors is essential for identifying high-risk individuals who may benefit from targeted screening or prevention strategies.
Non-Modifiable Risk Factors
Age is the strongest demographic risk factor; the incidence of pancreatic cancer rises steeply after age 50 and peaks in the seventh to eighth decades, with a lifetime risk of approximately 1 in 64 by age 80 [116]B2b. Hereditary predisposition underlies an estimated 5-10% of cases. Pathogenic germline variants in BRCA1, BRCA2, PALB2, ATM, CDKN2A, STK11, and the genes (MLH1, MSH2, MSH6) dramatically elevate risk [92]A1c[93]A1c[94]A1c. For BRCA2 carriers, the lifetime risk is 5-10% (RR 3-6); for STK11 carriers with Peutz-Jeghers syndrome, risk exceeds 30% by age 70 [136]D5[138]B2b. Family history without a known germline mutation (familial pancreatic cancer) confers a RR of approximately 2.3 for one affected first-degree relative, rising to 6.4 with two or more [94]A1c[123]D5. Pre-existing chronic pancreatitis, whether hereditary or due to non-genetic causes, increases risk approximately three-fold (OR 2.71, 95% CI 1.96-3.74) even after excluding cases diagnosed within two years of pancreatitis onset [109]B3a. Cystic fibrosis (CF) is associated with a 5- to 10-fold increased risk of pancreatic cancer, likely mediated by exocrine dysfunction and chronic inflammation [12]A1a. ABO blood group, non-O types, show a modest increase in risk (OR ~1.4) [116]B2b.
Modifiable Risk Factors
Cigarette smoking is the most consequential modifiable risk factor. Current smokers have an RR of approximately 2.1 (95% CI 1.8-2.4), and the risk is dose-dependent, with a 20+ pack-year history doubling the risk further [116]B2b[150]D5. Risk declines after cessation, but a residual elevation persists for 15-20 years [96]B2b. Obesity (BMI ≥30 kg/m²) increases incident risk by 10-20% per 5-unit BMI increment (RR 1.10, 95% CI 1.07-1.14) and also worsens survival (HR 1.53 for BMI ≥35) [99]A1a[126]B2b. Central adiposity (waist-to-hip ratio) appears to be an independent risk factor, even after adjusting for BMI [21]B2a. Heavy alcohol consumption (≥30 g/day in men, ≥16 g/day in women) is linked to a 60% increase in risk (OR 1.6, 95% CI 1.2-2.2), likely mediated through recurrent acute and chronic pancreatitis [110]B3a. Light-to-moderate consumption does not appear to elevate risk [110]B3a. Dietary acrylamide and high vitamin D intake have been associated with elevated odds in some pooled analyses, but evidence remains inconclusive [108]B3a[107]B3a. Periodontal disease and edentulism have been linked to a modest increase in risk, possibly via systemic inflammation or oral microbiome dysbiosis (summary RR ~1.5) [97]A1a[74]B2b. Hepatitis B virus (HBV) infection has been variably associated: a case-control study reported an OR of 2.18 for HBV surface antigen positivity [125]B3b. Radiation exposure, particularly to the pancreas field in childhood or young adulthood (e.g., Hodgkin lymphoma survivors), increases risk in a dose-dependent manner (RR ~2.3 after ≥20 Gy) [117]B3b.
Occupation and environment: Cadmium exposure (occupational or dietary) has been associated with pancreatic cancer in a recent meta-analysis (pooled OR 1.48, 95% CI 1.12-1.96) [54]A1a. Solid organ transplant recipients, especially those on long-term immunosuppression, have elevated rates (IRR ~1.5) [79]B2b.
Protective and Uncertain Factors
Diabetes type and duration: New-onset diabetes (≤3 years) is a paraneoplastic harbinger of pancreatic cancer in up to 1% of adults >50 years of age, with the diabetes often resolving after tumor resection [44]D5[42]A1c[27]B2c. Long-standing diabetes (≥5 years) is a modest independent risk factor (RR 1.5-2.0) [150]D5. use may attenuate risk, though data are mixed [150]D5. SGLT2 inhibitors have not been convincingly linked to risk reduction or increase [146]B2b. Coffee consumption, once controversially linked, shows a neutral association in dose-response meta-analyses (RR 1.13, 95% CI 0.99-1.29 after smoking adjustment) [98]A1a. Dietary fiber may be weakly protective (OR 0.69 for highest vs lowest quintile) [106]B3b. use and statin use have been associated with modest risk reduction in observational studies, but no randomized trial has confirmed benefit [116]B2b.
Risk Factor Summary Table
| Risk Factor | Approximate RR/OR | Strength of Evidence |
|---|---|---|
| Familial pancreatic cancer (≥1 1st-degree relative) | RR 2.3-6.4 | Moderate to strong [94]A1c[123]D5 |
| BRCA2 germline mutation | RR 3-6 | Strong [92]A1c[136]D5[138]B2b |
| Cigarette smoking (current) | RR 2.0-2.2 | Strong [116]B2b[150]D5 |
| Obesity (BMI ≥30) | RR 1.1 per 5 kg/m² | Strong [99]A1a[126]B2b |
| Chronic pancreatitis (≥2 years) | OR 2.7 | Strong [109]B3a |
| Heavy alcohol (≥30 g/day) | OR 1.6 | Moderate [110]B3a |
| Diabetes mellitus (≥5 years) | RR 1.5-2.0 | Moderate [44]D5[150]D5 |
| Cadmium exposure | OR 1.48 | Moderate [54]A1a |
| Periodontal disease | RR ~1.5 | Weak to moderate [97]A1a |
| Non-O blood group | RR ~1.4 | Weak [116]B2b |
Prevention and Screening Guidance
Population-based screening for sporadic pancreatic cancer is not recommended by any major guideline because the low incidence renders it cost-ineffective and the available imaging (EUS, MRI) has high false-positive rates [73]B2b[94]A1c. The NCCN recommends screening only for high-risk individuals: those with a known germline mutation (BRCA1/2, PALB2, ATM, CDKN2A, STK11, MLH1/MSH2) or a family history with ≥2 affected first-degree relatives [92]A1c[93]A1c. Screening typically begins at age 50 (or 10 years younger than the earliest family diagnosis) and uses annual endoscopic ultrasound (EUS) and/or MRI/MRCP [57]D5[153]B2b. The ASCO Provisional Clinical Opinion similarly endorses risk assessment in all patients with newly diagnosed pancreatic adenocarcinoma to identify at-risk family members [94]A1c. Smoking cessation remains the single most impactful preventive intervention. Weight , metformin use in diabetics, and avoidance of heavy alcohol are prudent, though data on direct risk reduction are observational. The USPSTF assigns a D rating to routine screening in asymptomatic adults, citing insufficient evidence of benefit and potential harms [73]B2b[94]A1c[124]D5.
Pearl: Cigarette smoking, obesity, new-onset diabetes, and a family history of pancreatic cancer or a high-risk germline mutation are the dominant risk identifiers; screening with annual EUS/MRI is reserved for the ~10% of at-risk individuals and can detect resectable, early-stage disease, improving survival in carefully selected surveillance programs [73]B2b[93]A1c[124]D5.
Histopathology and Molecular Biology
- ▸PDAC accounts for >90% of pancreatic cancers; rare variants (medullary, colloid, acinar) have distinct molecular profiles and therapeutic implications.
- ▸Four canonical driver genes (KRAS, TP53, CDKN2A, SMAD4) are mutated in the majority of PDAC; KRAS wild-type tumors often harbor BRAF deletions or fusions.
- ▸Transcriptomic subtypes (classical vs basal-like) predict prognosis and chemotherapy sensitivity, with basal-like associated with worse outcomes and resistance to gemcitabine.
The histologic subtype and molecular drivers of pancreatic cancer dictate prognosis and guide systemic therapy selection. Over 90% of pancreatic exocrine tumors are pancreatic ductal adenocarcinoma (PDAC), a gland-forming malignancy characterized by infiltrating glands embedded in a dense desmoplastic stroma [175]B2b. The remaining 5-10% comprise rare histologic variants, medullary, colloid (mucinous noncystic), acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary neoplasm, each with distinct biology and actionable alterations [162]D5. Medullary carcinomas are often microsatellite instability-high (MSI-H) and enriched for DNA mismatch repair deficiency, while colloid carcinomas arise from intraductal papillary mucinous neoplasms (IPMNs) and carry a better prognosis [162]D5[171]D5. Acinar cell carcinomas frequently harbor BRAF fusions or other MAPK pathway alterations and are KRAS wild-type [162]D5[172]D5.
Molecular Drivers
PDAC is driven by recurrent somatic mutations in four canonical genes: KRAS (mutated in >90% of cases), TP53 (~70%), CDKN2A (~95% inactivated), and SMAD4 (~55%) [175]B2b. KRAS mutations, most commonly G12D, G12V, and G12R, constitutively activate the MAPK and PI3K signaling cascades, promoting proliferation and metabolic reprogramming [200]D5[182]D5. TP53 loss disables cell-cycle checkpoints and apoptosis. CDKN2A inactivation (via deletion, mutation, or promoter methylation) removes the G1/S checkpoint. SMAD4 loss disrupts TGF-β signaling, facilitating invasion and metastasis [175]B2b. Additional recurrent alterations include GNAS (in IPMN-associated PDAC), RNF43 (Wnt pathway regulator), ARID1A (chromatin remodeling), TGFβR2, RREB1, and PBRM1 [175]B2b. KRAS wild-type tumors often harbor alternative driver events such as BRAF deletions (4.2% of KRAS wild-type), CTNNB1 mutations, or gene fusions [172]D5[175]B2b.
Transcriptomic Subtypes
Bulk transcriptomic profiling has defined two consensus molecular subtypes: classical (pancreatic/epithelial) and basal-like (squamous/quasi-mesenchymal) [166]D5[186]D5. The classical subtype is characterized by high expression of GATA6, HNF1A, and adhesion-related genes, and is associated with better prognosis and greater sensitivity to modified FOLFIRINOX [163]B2b[186]D5. The basal-like subtype shows upregulation of TP63, KRT5, and epithelial-mesenchymal transition (EMT) genes, and confers a worse prognosis with relative resistance to -based regimens [165]B3b[186]D5. Single-cell RNA sequencing has revealed that most PDACs are an admixture of both subtypes, with the basal-like fraction driving aggressive behavior [188]B2b[187]B2b. Spatial transcriptomics further demonstrates that basal-like tumor cells are enriched in regions with CXCL10+ fibroblasts, creating an immunosuppressive niche [187]B2b.
Tumor Microenvironment and Neural Invasion
The PDAC microenvironment is profoundly desmoplastic, with abundant cancer-associated fibroblasts (CAFs), immune cells, and extracellular matrix components that promote immune evasion and chemoresistance [198]D5[173]D5. Neural invasion is a hallmark of PDAC, occurring in >80% of resected specimens, and is mediated by Schwann cell subsets and NRP2+ endoneurial fibroblasts [174]B2b. Tumors recruit nerves by secreting nerve growth factor, and in turn, nerves supply serine to support tumor growth [180]D5. The immune microenvironment is typically T-cell excluded, with low neoantigen-reactive T-cell infiltration and high expression of immunosuppressive factors [144]C4[173]D5.
Therapeutic Implications
Molecular profiling is increasingly used to guide therapy. Patients with MSI-H/dMMR tumors (≈1-2% of PDAC) are eligible for regardless of histology [195]B2b. Tumors with homologous recombination deficiency (e.g., BRCA1/2, PALB2, ATM mutations) may respond to platinum-based chemotherapy and PARP inhibitors such as olaparib [167]B2b. KRAS G12C inhibitors (e.g., sotorasib, adagrasib) are approved for KRAS G12C-mutated PDAC (≈1-2%) [200]D5. Emerging transcriptomic signatures, such as the G-chemo vs F-chemo biomarker derived from computational histology, aim to predict benefit from gemcitabine-based versus fluoropyrimidine-based chemotherapy [165]B3b. The NCCN and ESMO guidelines now recommend molecular testing for actionable alterations, including MSI, BRCA1/2, and NTRK fusions, in advanced disease [157]B2b[162]D5.
Pearl: Histologic subtype and molecular drivers, particularly KRAS, TP53, CDKN2A, SMAD4, and transcriptomic class, stratify prognosis and increasingly guide targeted therapy and chemotherapy selection in pancreatic cancer [175]B2b[186]D5[165]B3b.
| Gene | Alteration Frequency | Functional Consequence | Therapeutic Implication |
|---|---|---|---|
| KRAS | >90% | Constitutive MAPK/PI3K activation | KRAS G12C inhibitors (sotorasib, adagrasib) for G12C subset [200]D5 |
| TP53 | ~70% | Loss of cell-cycle checkpoint, apoptosis | No direct targeted therapy; synthetic lethality strategies under investigation |
| CDKN2A | ~95% (inactivated) | Loss of G1/S checkpoint | No direct targeted therapy |
| SMAD4 | ~55% | Disrupted TGF-β signaling, enhanced invasion | No direct targeted therapy |
| GNAS | ~5% (IPMN-associated) | Constitutive cAMP signaling | No direct targeted therapy |
| BRAF | 4.2% of KRAS WT | MAPK activation | RAF dimer inhibitors (e.g., LY3009120) under investigation [172]D5 |
| MSI-H/dMMR | 1-2% | Mismatch repair deficiency | Pembrolizumab (anti-PD-1) [195]B2b |
| BRCA1/2, PALB2, ATM | 5-7% (germline) | Homologous recombination deficiency | Platinum chemotherapy, PARP inhibitors (olaparib) [167]B2b |
Clinical Presentation
- ▸Painless jaundice is the classic presentation for head tumors, while body/tail tumors present with epigastric back pain and weight loss.
- ▸New-onset diabetes occurs in up to 80% of patients and can precede diagnosis by 1-2 years, especially in thin older adults.
- ▸Courvoisier's sign (palpable gallbladder in jaundice) strongly suggests malignant biliary obstruction.
Presenting Symptoms
Most patients present with advanced, incurable disease because early pancreatic cancer is asymptomatic [204]A1c. The symptom profile depends on tumor location. Cancers of the pancreatic (60-70% of cases) obstruct the distal common bile duct, producing painless jaundice with pruritus, dark urine, and pale stools. Body and tail tumors remain silent longer, presenting with epigastric pain that radiates to the back, often worse when supine and relieved by leaning forward. Weight loss is nearly universal; a meta-analysis found a mean loss of 5.2 kg (95% CI 4.1-6.3 kg) in the year before diagnosis [46]B2a. New-onset diabetes occurs in up to 80% of patients and can precede diagnosis by 1-2 years, especially in thin older adults without family history [44]D5[42]A1c. Other common symptoms include anorexia, early satiety, nausea, steatorrhea, and fatigue. Depression is reported in 30-50% of patients and may be the earliest manifestation [204]A1c.
Physical Examination Findings
Jaundice and scleral icterus are the most visible signs. Courvoisier's sign, a palpable, non-tender gallbladder in a jaundiced patient, suggests malignant obstruction of the common bile duct (positive predictive value >90%). An epigastric mass may be palpable in advanced body/tail tumors. indicates peritoneal carcinomatosis and carries a median survival of only 2.5 months after diagnosis [247]C4. Virchow's node (left supraclavicular lymphadenopathy) and Trousseau's sign (migratory superficial thrombophlebitis) are classic but uncommon findings. Cachexia with muscle wasting is evident in most patients at presentation [259]D5.
Neurological and Paraneoplastic Findings
Paraneoplastic syndromes are rare but include and autonomic dysfunction from celiac plexus invasion. Depression is the most common neuropsychiatric finding and may be mediated by tumor-derived cytokines [204]A1c.
Phenotypic Variants
| Variant | Key Features | Frequency |
|---|---|---|
| Head tumors | Painless jaundice, pruritus, Courvoisier's sign | 60-70% |
| Body/tail tumors | Epigastric/back pain, weight loss, no jaundice until late | 20-30% |
| Acinar cell carcinoma | May secrete lipase → , polyarthralgia, eosinophilia | <1% |
| Medullary carcinoma | Often MSI-H, may present with family history of | <1% |
Red Flags
- Jaundice + weight loss >10% over 6 months requires urgent imaging [46]B2a.
- New-onset diabetes in a non-obese patient aged >50 years without family history, consider pancreatic cancer screening [42]A1c.
- Unexplained epigastric pain radiating to the back, especially with supine exacerbation.
- Acute pancreatitis in an older adult without or alcohol use may be the first presentation of an underlying tumor.
Atypical Presentations
Pancreatic cancer can first manifest as acute pancreatitis (3-5% of cases), migratory thrombophlebitis, or depression without abdominal symptoms. Rarely, a pancreatic mass is found to be a metastasis from another primary (e.g., lung adenocarcinoma) [220]C4. Peritoneal carcinomatosis may present with malignant ascites and bowel obstruction [45]C4.
Pearl: New-onset diabetes in a thin older adult without obesity or family history should prompt consideration of pancreatic cancer, as it may precede diagnosis by 1-2 years and offers a window for earlier detection [42]A1c[44]D5.
Biopsy and Histologic Diagnosis
- ▸EUS-guided FNA or FNB is the gold standard for tissue diagnosis of pancreatic cancer, with sensitivity 85-90% and specificity >95%.
- ▸Rapid on-site evaluation (ROSE) improves specimen adequacy and reduces repeat procedures.
- ▸Biopsy material is sufficient for both histologic diagnosis and molecular profiling (KRAS, MMR, BRCA1/2, NGS), enabling precision therapy.
Tissue acquisition for pancreatic cancer relies almost exclusively on endoscopic ultrasound (EUS)-guided sampling, which has supplanted percutaneous approaches due to superior safety and diagnostic accuracy. The gold-standard diagnostic test is EUS-guided fine-needle aspiration (EUS-FNA) or, increasingly, EUS-guided fine-needle biopsy (EUS-FNB) using core needles. Sensitivity for solid pancreatic masses is 85-90% and specificity exceeds 95% [289]D5. Rapid on-site evaluation (ROSE) by a cytopathologist improves adequacy rates to >90% and reduces the need for repeat procedures [289]D5.
Cystic Lesions
For pancreatic cystic lesions, EUS-FNA with cyst fluid analysis is the cornerstone. Carcinoembryonic antigen (CEA) >192 ng/mL distinguishes mucinous from non-mucinous cysts with ~80% accuracy [285]D5. Cyst fluid glucose <50 mg/dL and amylase levels further refine classification. When cytology is equivocal, EUS-through-the-needle biopsy (EUS-TTNB) provides histologic cores with diagnostic yield >80% and strong concordance with surgical pathology [181]D5.
Handling and Processing
Specimens should be processed for cell block preparation, which enables immunohistochemistry (IHC) and molecular testing. For next-generation sequencing (NGS), formalin-fixed paraffin-embedded (FFPE) blocks are standard; if RNA sequencing is planned, dedicated RNA-stabilizing media is preferred [286]D5. Core biopsies (EUS-FNB) yield more tissue than FNA and are increasingly used for comprehensive genomic profiling [286]D5.
Histologic Hallmarks
Pancreatic ductal adenocarcinoma (PDAC) shows infiltrating glands embedded in dense desmoplastic stroma, with nuclear pleomorphism, mitoses, and perineural invasion. A standard IHC panel includes CK7+, CK19+, MUC1+, MUC4+; loss of SMAD4 expression occurs in ~55% of cases and is highly specific for PDAC [289]D5. Aberrant p53 (overexpression or null pattern) is seen in ~70% [289]D5. These markers help distinguish PDAC from chronic pancreatitis, , and other pancreatic neoplasms.
Molecular Testing from Biopsy
Biopsy material is the primary source for molecular profiling. KRAS mutation testing (codons 12, 13, 61) is positive in >90% of PDAC and can be performed on limited cytology specimens [279]B2b. Mismatch repair (MMR) IHC or microsatellite instability (MSI) testing is recommended for all patients to identify and eligibility for immune checkpoint inhibitors [275]C4. Germline and somatic testing for BRCA1/2 and PALB2 mutations guides PARP inhibitor therapy [282]C4. NGS panels can detect actionable alterations (NTRK fusions, HER2 amplification, IDH1 mutations) in 10-15% of cases [286]D5. When tissue is insufficient, circulating tumor DNA (ctDNA) analysis is a complementary approach, but tissue remains the gold standard [277]C4[287]D5.
Diagnostic Algorithm
Step 1: Cross-sectional imaging (CT or MRI) identifies a pancreatic mass or cystic lesion. Step 2: EUS-FNA or EUS-FNB with ROSE for solid lesions; for cystic lesions, EUS-FNA with cyst fluid analysis ± EUS-TTNB. Step 3: Histologic confirmation with IHC (CK7, CK19, MUC1, SMAD4, p53). Step 4: Molecular profiling (KRAS, MMR, BRCA1/2, NGS) on the same biopsy specimen to guide targeted therapy and clinical trial enrollment.
Pearl: EUS-guided tissue acquisition with ROSE achieves >90% diagnostic accuracy for solid pancreatic masses, and the same biopsy specimen can be used for comprehensive molecular profiling, including KRAS, MMR, and BRCA1/2 testing, which is essential for modern precision oncology [289]D5[286]D5.
| Marker | Expression in PDAC | Diagnostic Utility |
|---|---|---|
| CK7 | Positive | Supports ductal origin |
| CK19 | Positive | Supports ductal origin |
| MUC1 | Positive | Distinguishes from benign |
| MUC4 | Positive | Highly specific for PDAC |
| SMAD4 | Lost in ~55% | Loss is specific for PDAC |
| p53 | Overexpressed or null in ~70% | Aberrant pattern suggests malignancy |
Imaging
- ▸Multiphase CT is the primary staging modality; MRI is reserved for problem-solving and surveillance in high-risk individuals.
- ▸PET/CT has a role in metabolic response assessment but is not routine for initial staging.
- ▸EUS provides superior local staging and is the preferred method for tissue acquisition.
Multiphase contrast-enhanced CT is the cornerstone of pancreatic cancer staging, with a dedicated pancreas protocol achieving sensitivity >90% for tumors ≥2 cm [227]D5. The NCCN guidelines recommend triple-phase CT (noncontrast, arterial, portal venous) with thin slices (≤3 mm) and multiplanar reformats to assess the primary tumor, arterial involvement (celiac, SMA, hepatic), venous involvement (portal vein, SMV), and distant metastases [206]A1c[227]D5. Standardized reporting using the Society of Abdominal Radiology and American Pancreatic Association template improves communication and staging consistency [227]D5.
MRI and MRCP
MRI with MRCP serves as a problem-solving tool when CT is equivocal for liver metastases or vascular invasion, detecting occult liver lesions in 10-15% of patients initially deemed resectable on CT [310]A1a. MRCP delineates ductal anatomy, with main pancreatic duct dilation (≥5 mm) and stenosis raising suspicion for malignancy [320]B2b. For high-risk individuals (familial pancreatic cancer, germline mutation carriers), annual MRI/MRCP with or without EUS is the recommended surveillance strategy, detecting precursor lesions and early-stage PDAC with improved resectability and survival [317]B2b[329]B2b[73]B2b. The PRECEDE consortium uses MRI as the primary surveillance modality [226]B2b.
Endoscopic Ultrasound
EUS provides superior local T-staging and N-staging compared to CT, with high-resolution assessment of tumor size and peripancreatic invasion [332]D5. It is the preferred method for tissue acquisition via fine-needle aspiration or biopsy, achieving diagnostic accuracy >90% [332]D5. Contrast-enhanced EUS (CE-EUS) helps differentiate pancreatic cancer from mass-forming pancreatitis by evaluating perfusion patterns [332]D5.
PET/CT
FDG-PET/CT is not routinely recommended for initial staging by NCCN but may be considered for detecting occult metastases in high-risk patients [206]A1c. In the MPACT trial, metabolic response (decrease in SUVmax) predicted survival, particularly in patients with normal baseline CA19-9 levels [300]A1b[313]D5. Emerging tracers show promise: [68Ga]Ga-FAPI-04 demonstrates higher SUVmax than FDG for primary tumors and lymph nodes [237]B2b; investigational agents targeting CA19-9 [309]C4, transferrin receptor [326]D5, CDCP1 [327]D5, and EphA2 [336]C4 are in early clinical evaluation.
Staging Laparoscopy
Staging laparoscopy identifies peritoneal metastases missed by cross-sectional imaging in 10-15% of patients [311]D5. Selective use is recommended for patients with locally advanced disease, high CA19-9, or equivocal imaging findings, as routine laparoscopy does not improve outcomes in all resectable patients [311]D5.
Emerging Techniques
Artificial intelligence (AI) models on CT can detect pancreatic cancer with AUC >0.90, identifying both direct (mass) and indirect (parenchymal atrophy, MPD dilation) signs [319]B2c[334]B3b. Multimetric MRI (diffusion-weighted, dynamic contrast-enhanced) captures early response to KRAS inhibitors [321]C4. The pRECIST consensus incorporates PET metabolic activity into response criteria for clinical trials [308]A1c.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine PET/CT for initial staging? | NCCN: not recommended [206]A1c | ESMO: may be considered [314]D5 | Category 2A vs expert opinion | Reserved for high-risk or equivocal cases |
| Routine staging laparoscopy? | Some centers: routine for all resectable [311]D5 | Others: selective based on CA19-9 and imaging [311]D5 | No consensus | Selective use reduces unnecessary procedures |
Pearl: A dedicated pancreas protocol CT with triple-phase imaging and thin slices is essential for accurate staging; MRI should be added when CT is equivocal for liver metastases or vascular involvement, and annual MRI/MRCP is recommended for surveillance in high-risk individuals [227]D5[310]A1a[317]B2b.
| Modality | Strengths | Limitations | Key Indication |
|---|---|---|---|
| CT (pancreas protocol) | High spatial resolution, vascular assessment, liver metastases | Limited for small tumors, equivocal vascular invasion | Primary staging, resectability assessment |
| MRI/MRCP | Superior soft tissue contrast, ductal anatomy, liver lesion characterization | Longer acquisition, motion artifacts, lower availability | Problem-solving, high-risk surveillance |
| EUS | High-resolution local staging, tissue acquisition | Operator-dependent, limited for distant metastases | T/N staging, biopsy |
| PET/CT | Metabolic activity, occult metastases | False positives (inflammation), limited spatial resolution | Response assessment, equivocal findings |
Molecular Diagnostics and Biomarkers
- ▸NCCN and ASCO recommend germline genetic testing for all patients with pancreatic adenocarcinoma, and somatic NGS for all metastatic/unresectable disease.
- ▸Actionable alterations (BRCA1/2, PALB2, ATM, MSI-H, TMB-H, NRG1 fusions, NTRK fusions) are found in ~15-20% of PDAC and directly inform targeted therapy or immunotherapy.
- ▸CA 19-9 is the standard serum biomarker for monitoring, but its absence in Lewis-negative patients (~5-10%) can be circumvented by DUPAN-2; it has no role in screening due to inadequate sensitivity and specificity.
The central challenge of pancreatic cancer , that most patients present with advanced, treatment-resistant disease, is being addressed by a rapidly maturing molecular diagnostic framework that identifies actionable alterations in tumor tissue, blood, and cyst fluid. Molecular testing is the gate to targeted and immune therapy, and the NCCN recommends germline testing for all patients with and somatic profiling for those with metastatic disease [93]A1c[94]A1c[349]A1c. The CAP now similarly endorses broad genomic profiling as standard of care.
Serum CA 19-9 and Its Limitations
CA 19-9 remains the only widely used serum biomarker, but its role is confined to monitoring treatment response and detecting recurrence, not screening or diagnosis. In the MPACT trial, a CA 19-9 decline of any magnitude at 8 weeks predicted improved OS (median 11.1 versus 5.4 months in patients without decline; HR not reported) [339]A1b. A ≥50% fall after two cycles of chemotherapy is associated with longer survival across multiple studies [347]A1b. CA 19-9 is neither sensitive nor specific enough for early detection: it is elevated in benign jaundice, pancreatitis, and 5-10% of the population are Lewis antigen-negative (FUT3-null) and cannot synthesize CA 19-9 at all [224]D5[312]B3b. For these patients, DUPAN-2 can serve as an alternative; defining FUT2/FUT3 genotype-specific reference ranges improves diagnostic performance for DUPAN-2 and CA 19-9 [121]B3b.
Circulating Tumor DNA (ctDNA) and Exosomes
Liquid biopsy has emerged as both a complement and alternative to tissue genotyping. ctDNA detection by Safe-SeqS targeting KRAS mutations is feasible in resectable pancreatic cancer: postoperative ctDNA positivity is a strong predictor of recurrence (HR not calculable from single-arm data; median recurrence-free survival not reached in ctDNA-negative vs 6.9 months in ctDNA-positive) [279]B2b. In the LAP07 trial, CTC detection by CellSearch in locally advanced disease was uncommon (detection rate not specified) but, when present, conferred a worse prognosis [337]A1b. Exosome-derived DNA and RNA enable whole-genome and transcriptome profiling even when tissue is scant; surfaceome-based enrichment (e.g., for Glypican-1) can isolate cancer-specific exosomes, improving mutation detection [278]C4[350]C4. A fragmentomics-based cfDNA model using shallow whole-genome sequencing detected PDAC with an AUC of 0.9799 in training and 0.9622 in validation, and predicted disease up to 298 days before conventional diagnosis [140]B3b[351]B2b.
Tumor Tissue Genotyping and Actionable Alterations
Tissue-based next-generation sequencing (NGS) should target a panel of established drivers and therapeutically relevant genes. KRAS mutations (G12D, G12V, G12R) occur in >90% of PDAC; the G12R variant, paradoxically common in PDAC yet rare in lung cancer, is impaired in PI3K signaling and macropinocytosis [365]D5. Homologous recombination deficiency (HRD) due to germline or somatic alterations in BRCA1, BRCA2, PALB2, and ATM is found in 10-15% of PDAC and confers sensitivity to platinum agents and PARP inhibitors. In a phase II trial of niraparib for advanced PDAC with germline/somatic BRCA1/2, PALB2, ATM, or CHEK2 alterations, the 6-month PFS rate was 30% [348]B2b. Microsatellite instability-high (MSI-H) and high tumor mutational burden (TMB-H; ≥10 mut/Mb) are rare (<2%) but define a subset responsive to regardless of histology [105]C4[360]B2b. NRG1 fusions (e.g., ATP1B1-NRG1) are oncogenic drivers that can be targeted with the bispecific antibody zenocutuzumab 750 mg IV every 2 weeks, which achieved an overall response rate of 40% in NRG1 fusion-positive pancreatic cancer [219]C4[362]D5. Other rare but actionable fusions involve NTRK1/2/3, ALK, and ROS1 [162]D5[354]D5.
Molecular Subtypes and Transcriptomic Profiling
PDAC segregates into classical and basal-like transcriptional subtypes, with the basal-like subtype conferring a significantly worse prognosis and relative resistance to FOLFIRINOX [264]B3b[369]B2b. The PurIST (Purity Independent Subtyping) classifier allows single-sample assignment and has been validated in clinical trial cohorts, enabling stratification for subtype-directed therapy [264]B3b. Single-cell RNA sequencing has further revealed intratumoral heterogeneity, with a KRT17⁺/CXCL8⁺ intermediate cell population that co-expresses classical and basal markers and recruits myeloid cells [372]D5. HMGA2 expression identifies basal-like disease in IHC and is a strong independent predictor of poor survival [373]B2b.
Cyst Fluid Biomarkers
For the 10-15% of PDACs that arise from intraductal papillary mucinous neoplasms (IPMNs), cyst fluid analysis can identify high-grade dysplasia or invasive carcinoma. CEA >192 ng/mL distinguishes mucinous from non-mucinous cysts with ~80% accuracy [285]D5. Molecular markers, KRAS/GNAS mutations, improve specificity, and integrated metabolomic profiling has identified polyamine metabolites as promising progression markers, outperforming CA 19-9 in cyst fluid [189]B2b[367]B3b.
Comprehensive Recommended Testing Algorithm
| Test | Population | Target | Implication | Recommendation Source |
|---|---|---|---|---|
| Germline NGS | All PDAC | BRCA1/2, PALB2, ATM, CHEK2, MLH1/MSH2 | PARP inhibitor eligibility; hereditary cancer syndrome | NCCN Category 1 [93]A1c[94]A1c |
| Somatic NGS | Metastatic/unresectable PDAC | KRAS, BRCA1/2, PALB2, ATM, MSI, TMB, NTRK, NRG1, ALK, ROS1 | Targeted therapy, immunotherapy | NCCN Category 2A [349]A1c |
| MSI/TMB IHC or NGS | All advanced PDAC | MSI-H, TMB ≥10 mut/Mb | Pembrolizumab eligibility | FDA label [105]C4 |
| CA 19-9 | Monitoring, post-resection surveillance | Serum | Prognosis, treatment response | ASCO/EGTM [95]A1c[224]D5 |
| ctDNA | Inadequate tissue, monitoring | KRAS, other drivers | Early detection, recurrence monitoring, resistance profiling | [279]B2b[277]C4 |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Universal germline testing for all PDAC? | NCCN and ASCO: Yes, for all patients [93]A1c[94]A1c | ESMO: Consider in patients with family history or young age | Consensus is shifting toward universal | Missed hereditary syndromes if testing only selected |
| Is somatic profiling required for all stages? | NCCN: Yes, for metastatic disease [349]A1c | CAP: Yes, for all PDAC | NCCN restricts to metastatic; CAP broader | Cost and tissue adequacy limit universal testing |
Pearl: Molecular testing, germline and somatic, is no longer optional in pancreatic cancer: it identifies hereditary syndromes, enables PARP inhibitor therapy for HRD-positive disease, and uncovers rare but actionable drivers (NRG1 fusions, MSI-H, NTRK fusions) that can dramatically alter the therapeutic course. CA 19-9, while imperfect, remains the workhorse biomarker for monitoring treatment response, though it cannot be used for screening.
Staging
- ▸Staging in pancreatic cancer uses both the AJCC TNM system for prognosis and the NCCN resectability classification to guide treatment decisions.
- ▸High-quality multiphase CT or MRI is essential for assessing vascular involvement; staging laparoscopy detects occult peritoneal metastases in 10-20% of patients.
- ▸Molecular markers such as ctDNA and TGFβ pathway alterations are emerging as adjuncts to traditional staging.
Staging determines whether a patient is a candidate for curative-intent resection or will require palliative systemic therapy. The NCCN resectability classification, not the stage alone, drives the initial treatment decision [205]A1c.
AJCC TNM Staging (8th Edition)
The AJCC 8th edition staging system for pancreatic ductal adenocarcinoma stratifies patients by tumor extent (T), nodal involvement (N), and metastasis (M). The table below summarizes the stage groupings and their corresponding 5-year survival rates.
| Stage | T | N | M | 5-Year Survival (approximate) |
|---|---|---|---|---|
| 0 | Tis | N0 | M0 | - |
| IA | T1 | N0 | M0 | 30-40% |
| IB | T2 | N0 | M0 | 20-30% |
| IIA | T3 | N0 | M0 | 15-20% |
| IIB | T1-T3 | N1 | M0 | 10-15% |
| III | T4, any T | N2, any N | M0 | 5-10% |
| IV | Any T | Any N | M1 | <5% |
T1: tumor ≤2 cm; T2: >2 cm but ≤4 cm; T3: >4 cm; T4: tumor involves celiac axis, superior mesenteric artery, or common hepatic artery. N1: 1-3 positive nodes; N2: ≥4 positive nodes. M1: distant metastasis [205]A1c.
NCCN Resectability Classification
The NCCN guidelines define four categories based on the relationship of the tumor to adjacent vascular structures on high-quality multiphase CT or MRI [227]D5[310]A1a.
Resectable: No arterial contact (celiac axis, SMA, or hepatic artery). No or ≤180° contact with the superior mesenteric vein (SMV) or portal vein (PV) without vein contour irregularity.
Borderline Resectable: Tumor contact with the SMA ≤180°; contact with the celiac axis ≤180°; contact with the common hepatic artery without extension to the celiac axis or hepatic artery bifurcation; or contact with the SMV/PV >180° or ≤180° with vein contour irregularity or thrombosis but with suitable vessel proximal and distal for reconstruction.
Locally Advanced (Unresectable): Tumor contact with the SMA >180°; contact with the celiac axis >180°; or unreconstructable SMV/PV involvement due to tumor thrombus or extension to the proximal jejunal branch.
Metastatic: Distant metastases (liver, peritoneum, lung, or distant lymph nodes) [205]A1c.
Role of Staging Laparoscopy
Despite advances in imaging, staging laparoscopy detects occult peritoneal or liver metastases in 10-20% of patients who appear resectable on CT, preventing unnecessary laparotomy [311]D5. The NCCN recommends staging laparoscopy for patients with borderline resectable or locally advanced disease, and selectively for those with resectable disease and high-risk features (e.g., CA 19-9 >1000 U/mL, large tumors) [205]A1c[311]D5.
Molecular and Biomarker Staging
Emerging data integrate molecular features into staging. Circulating tumor DNA (ctDNA) detection of mutant KRAS in plasma is associated with worse prognosis and may identify occult metastatic disease [420]B2b[406]B2b. TGFβ pathway alterations, particularly SMAD4 inactivation, are enriched in de novo metastatic PDAC, whereas TGFBR2 inactivation is more common in locally advanced tumors [415]B2b. These molecular distinctions may refine staging in the future.
Impact on
Staging directly dictates the treatment pathway:
- Resectable: Upfront surgical resection followed by adjuvant chemotherapy (e.g., modified FOLFIRINOX or plus ) [205]A1c[412]B2b.
- Borderline Resectable: Neoadjuvant chemotherapy (often FOLFIRINOX) with or without chemoradiation, then restaging for potential resection [395]D5[399]B2b.
- Locally Advanced: Systemic chemotherapy (FOLFIRINOX or gemcitabine-based combinations) with or without subsequent chemoradiation; a subset may become resectable after response [210]A1a[271]A1b.
- Metastatic: Palliative chemotherapy (FOLFIRINOX, gemcitabine plus , or gemcitabine plus capecitabine) [386]A1b[388]A1b.
Accurate staging is the cornerstone of pancreatic cancer management, guiding the sequence and intensity of therapies.
Pearl: The NCCN resectability classification, based on vascular involvement on CT/MRI, is the primary determinant of treatment strategy; staging laparoscopy should be used selectively to detect occult metastases that would change management [205]A1c[311]D5.
| Stage | T | N | M | 5-Year Survival (approximate) |
|---|---|---|---|---|
| 0 | Tis | N0 | M0 | - |
| IA | T1 | N0 | M0 | 30-40% |
| IB | T2 | N0 | M0 | 20-30% |
| IIA | T3 | N0 | M0 | 15-20% |
| IIB | T1-T3 | N1 | M0 | 10-15% |
| III | T4, any T | N2, any N | M0 | 5-10% |
| IV | Any T | Any N | M1 | <5% |
Management Overview
- ▸Management is stratified by resectability: upfront surgery + adjuvant mFOLFIRINOX for resectable, neoadjuvant therapy for borderline resectable, induction chemotherapy for locally advanced, and multiagent chemotherapy for metastatic disease.
- ▸First-line options for metastatic PDAC include FOLFIRINOX, gemcitabine/nab-paclitaxel, and NALIRIFOX; maintenance olaparib is indicated for germline BRCA-mutated patients.
- ▸Molecular profiling (germline BRCA, MSI, KRAS G12C, NRG1 fusions) enables targeted therapy in a subset of patients and should be performed for all newly diagnosed cases.
of pancreatic cancer is determined by resectability status at diagnosis, with systemic therapy playing a central role across all stages. Treatment decisions require multidisciplinary evaluation and are guided by NCCN, ESMO, and ASCO guidelines [204]A1c[423]A1c[433]A1c. The following sections summarize the approach by disease stage; detailed protocols are provided in dedicated child pages.
Resectable Disease
For patients with anatomically resectable pancreatic ductal adenocarcinoma (PDAC) and good performance status, the standard of care is surgical resection followed by adjuvant chemotherapy. The PRODIGE 24 trial established modified FOLFIRINOX (mFOLFIRINOX) as the preferred adjuvant regimen: 85 mg/m², 150 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m² over 46 hours every 2 weeks for 12 cycles [13]A1b (1b). Five-year overall survival was 43.2% with mFOLFIRINOX versus 31.4% with (HR 0.64, 95% CI 0.52-0.79; NNT = 8 to prevent one death) [306]A1b (1b). For patients unable to tolerate mFOLFIRINOX, gemcitabine plus or gemcitabine alone are alternatives [204]A1c. Neoadjuvant therapy for resectable disease remains investigational; the SWOG S1505 trial showed no survival benefit for perioperative mFOLFIRINOX or gemcitabine/ over upfront surgery, though 50% of patients in the neoadjuvant arm failed to undergo resection [422]A1b (1b). The PREOPANC-2 trial reported no significant overall survival difference between neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable/borderline resectable disease [437]A1b (1b).
Borderline Resectable Disease
Borderline resectable PDAC is defined by tumor abutment of the superior mesenteric artery or portal vein. Neoadjuvant therapy is recommended to improve R0 resection rates and survival. The PREOPANC trial demonstrated a median overall survival of 17.1 months with neoadjuvant gemcitabine-based chemoradiotherapy versus 13.7 months with upfront surgery (HR 0.73, 95% CI 0.56-0.96; NNT = 9 to prevent one death) [426]A1b (1b). Long-term follow-up confirmed sustained benefit [425]A1b (1b). NCCN guidelines recommend neoadjuvant FOLFIRINOX or gemcitabine/nab- for 2-6 cycles, followed by restaging and surgery if feasible [204]A1c. The NEONAX trial showed perioperative gemcitabine/nab-paclitaxel improved 18-month DFS compared with adjuvant-only therapy (32.2% vs 14.1%) but did not meet its primary endpoint [424]A1b (1b).
Locally Advanced Unresectable Disease
For locally advanced pancreatic cancer (LAPC), induction chemotherapy is the cornerstone. A patient-level meta-analysis reported a median overall survival of 24.2 months with FOLFIRINOX and a conversion-to-resection rate of 28% [210]A1a (1a). The PRODIGE 29 (NEOPAN) trial found FOLFIRINOX superior to gemcitabine in LAPC: median PFS 15.0 vs 7.5 months (HR 0.57, 95% CI 0.44-0.74) [429]A1b (1b). After 3-6 months of induction chemotherapy, patients without progression may be considered for chemoradiotherapy (CRT) or ( ). The CONKO-007 trial reported a higher R0 resection rate with CRT after induction chemotherapy (25% vs 10%, P = 0.004) but no overall survival benefit [432]A1b (1b). Ablative radiation therapy (A-RT) has shown promising local control in selected patients [82]B3b (3b).
Metastatic Disease
First-line systemic therapy for metastatic PDAC depends on performance status. For patients with PS 0-1, FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² bolus then 2400 mg/m² over 46 hours every 2 weeks) improved median OS to 11.1 months versus 6.8 months with gemcitabine (HR 0.57, 95% CI 0.45-0.73; NNT = 4 to prevent one death) [440]A1b (1b). Gemcitabine plus nab-paclitaxel (gemcitabine 1000 mg/m², nab-paclitaxel 125 mg/m² on days 1, 8, 15 every 28 days) showed median OS 8.7 vs 6.6 months (HR 0.72, 95% CI 0.62-0.83; NNT = 5) [441]A1b (1b). The ESMO 2025 update recommends NALIRIFOX (nanoliposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², fluorouracil 2400 mg/m² every 2 weeks) as a new first-line option based on the NAPOLI 3 trial [433]A1c (1c). A network meta-analysis confirmed FOLFIRINOX and gemcitabine/nab-paclitaxel as the most effective regimens, with comparable efficacy [445]A1a (1a). For patients with germline BRCA1/2 mutations, maintenance olaparib 300 mg twice daily after at least 16 weeks of platinum-based chemotherapy without progression significantly improved PFS (HR 0.53, 95% CI 0.35-0.82; NNT = 4 to prevent progression) [14]A1b (1b); final OS analysis showed a numerical but not statistically significant benefit [427]A1b (1b). Second-line options include liposomal irinotecan plus fluorouracil/leucovorin (NAPOLI-1) or OFF regimen (oxaliplatin, folinic acid, fluorouracil) [430]A1b (1b).
First-Line Regimens for Metastatic Pancreatic Cancer
| Regimen | Dose | Key Trial | Median OS | HR (95% CI) | NNT |
|---|---|---|---|---|---|
| FOLFIRINOX | Oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², 400 mg/m² bolus + 2400 mg/m² over 46 h, q2w | PRODIGE 4/ACCORD 11 [440]A1b | 11.1 vs 6.8 mo | 0.57 (0.45-0.73) | 4 |
| Gemcitabine + nab-paclitaxel | Gem 1000 mg/m², nab-P 125 mg/m² d1,8,15 q28d | MPACT [441]A1b | 8.7 vs 6.6 mo | 0.72 (0.62-0.83) | 5 |
| NALIRIFOX | Nal-IRI 50 mg/m², oxaliplatin 60 mg/m², LV 400 mg/m², 5-FU 2400 mg/m² over 46 h, q2w | NAPOLI 3 [433]A1c | 11.1 vs 9.2 mo | 0.83 (0.70-0.99) | 12 |
| Gemcitabine + erlotinib | Gem 1000 mg/m² d1,8,15 q28d; erlotinib 100-150 mg PO daily | NCIC CTG PA.3 [3]A1b | 6.2 vs 5.9 mo | 0.82 (0.69-0.99) | 20 |
Targeted Therapy and Immunotherapy
All patients with PDAC should undergo germline testing for BRCA1/2, PALB2, and MSI status [204]A1c[92]A1c. For MSI-H/dMMR tumors, is approved regardless of line [252]B3b (3b). KRAS G12C inhibitors (sotorasib 960 mg daily, adagrasib) show activity in the 1-2% of PDAC with this mutation: objective response rate 21.1% in CodeBreaK100 [453]C4 (4). Novel agents such as the RAS(ON) multiselective inhibitor daraxonrasib and the KRAS G12D inhibitor MRTX1133 are under investigation [452]C4[503]D5. For NRG1 fusion-positive tumors, zenocutuzumab 750 mg IV every 2 weeks has received regulatory approval [219]C4 (4).
Palliative and Supportive Care
Pain management, nutritional support (pancreatic enzyme replacement therapy), and management of biliary obstruction are integral. Celiac plexus radiosurgery (single fraction 25 Gy) can reduce refractory pain [216]C4 (4). Venous thromboembolism prophylaxis with LMWH or DOACs is recommended per ITAC-CME guidelines [434]A1c (1c).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication for practice |
|---|---|---|---|---|
| Neoadjuvant therapy for resectable PDAC | NCCN, neoadjuvant therapy is an option but not standard; upfront surgery followed by adjuvant mFOLFIRINOX is preferred [204]A1c | ESMO, neoadjuvant therapy may be considered, especially for high-risk features; no strong recommendation [423]A1c | Moderate | Most centers use upfront surgery for clearly resectable disease; neoadjuvant approach reserved for borderline resectable or high-risk anatomic features. |
| First-line regimen choice in metastatic disease | ESMO 2025, NALIRIFOX is a new first-line option [433]A1c | NCCN, FOLFIRINOX or gemcitabine/nab-paclitaxel remain category 1 recommendations [204]A1c | Mild | NALIRIFOX is an alternative; no -to-head comparison with FOLFIRINOX exists. Choice depends on toxicity profile and availability. |
| Role of radiotherapy in LAPC | ASCO, CRT may be considered after induction chemotherapy for local control [432]A1b | ESMO, CRT is not routinely recommended; chemotherapy alone is preferred [423]A1c | Moderate | CRT can be used for conversion to resectability or symptom palliation; no survival benefit in unselected patients. |
Pearl: Resectability status dictates the treatment sequence; all patients with good performance status should receive multiagent chemotherapy, and germline testing for BRCA and MSI status is essential to identify targeted therapy opportunities (POLO, CodeBreaK100) [14]A1b[453]C4.
Prognosis and Prognostic Factors
- ▸Overall 5-year survival remains <10%, but prognosis is highly heterogeneous: R0-resected node-negative patients with classical-subtype tumors have median survival >24 months, while metastatic basal-like disease carries median <14 months [13, 369, 506].
- ▸Beyond TNM stage, validated prognostic factors include CA 19-9 dynamics [312], NLR [10], sarcopenia [246], the classical versus basal-like molecular subtype [369, 506], and specific KRAS mutant alleles (G12R favorable, G12D unfavorable) [260].
- ▸Recurrence after curative resection remains 70-80% within 2 years; long-term survivors often have persistent fatigue and psychological morbidity [122, 228, 551].
For pancreatic ductal adenocarcinoma (PDAC), 5-year survival across all stages remains below 10% and, for metastatic disease, median survival is only 11.1 months with / and 8.5 to 11.2 months with FOLFIRINOX [13]A1b[300]A1b[441]A1b. Survival has improved incrementally in the modern chemotherapy era, rising from a median of 4.3 months in 1997-2000 to 8.6 months in 2012-2017 in pooled AIO trial data [529]A1a. However, these figures obscure the wide heterogeneity in outcome driven by stage, biology, and treatment response. The strongest independent prognostic factor is resectability: patients who undergo margin-negative (R0) pancreatectomy achieve median survival of 24-28 months with adjuvant FOLFIRINOX [13]A1b or gemcitabine/ (ESPAC-4) [555]D5, whereas those with unresectable disease face a median of 8-11 months [429]A1b[445]A1a. Nodal involvement, perineural invasion, and lymphovascular space invasion (LVSI) each independently worsen prognosis even after R0 resection [553]D5[548]D5.
Prognostic factors beyond stage
Multiple validated factors refine risk beyond the staging system. Serum CA 19-9 level is a powerful, dynamic biomarker: a postoperative CA 19-9 < 90 U/mL at 3 months portends median survival of 25.6 months versus 14.8 months for higher levels, and a CA 19-9 decline >50% after induction therapy predicts a higher R0 resection rate in locally advanced disease [312]B3b[344]A1b. The neutrophil-to-lymphocyte ratio (NLR) is likewise independently prognostic; in a meta-analysis of 66 cohorts, an elevated pretreatment NLR conferred a pooled HR of 1.53 (95% CI 1.37-1.71) for overall survival across advanced cancers including PDAC [10]A1a. Performance status is consistently among the strongest predictors in advanced disease: patients with PS 0 survive a median 12.4 months versus 6.8 months for PS 2 [534]B2c. Venous thromboembolism (VTE) is both a complication and a negative prognostic signal; in 227 patients with unresectable PDAC, synchronous VTE at diagnosis independently predicted shorter survival (HR 1.62, 95% CI 1.18-2.22) [540]B2b.
| Prognostic factor | Favorable prognosis | Poor prognosis |
|---|---|---|
| Resectability | R0 resection, node-negative (stage I) | R1/R2 resection, N1/N2 disease [553]D5 |
| CA 19-9 | Postoperative normalization or >50% decline | Persistent elevation or rise during therapy [312]B3b[344]A1b |
| Performance status | ECOG PS 0-1 | ECOG PS ≥2 [534]B2c |
| NLR | Low NLR (<3-5) | High NLR (HR 1.53) [10]A1a |
| VTE | Absent | Present at diagnosis (HR 1.62) [540]B2b |
| Sarcopenia/MBR | Normal muscle/bone ratio | Low muscle-to-bone ratio (HR 1.8-2.0) [246]C4 |
| Molecular subtype | Classical (GATA6-high) | Basal-like (GATA6-low, HMGA2-high) [369]B2b[373]B2b[506]B2b |
| KRAS variant | KRAS G12R (node-sparing, improved survival) | KRAS G12D (higher EMT, shorter survival) [260]B3b |
Molecular subtypes as prognostic stratifiers
Transcriptomic classification has redefined prognosis at the molecular level. The classical subtype, characterized by high GATA6 expression, carries a median overall survival of 24.8 months in advanced disease versus 13.7 months for the basal-like subtype (HR 2.14, 95% CI 1.37-3.34) [369]B2b[506]B2b. In the COMPASS trial, basal-like tumors had a response rate of only 10% to gemcitabine/nab- versus 38% for classical tumors, whereas FOLFIRINOX showed less subtype-dependent differential benefit [506]B2b. HMGA2 protein expression is a robust surrogate for basal-like disease, identifying patients with significantly shorter survival and greater chemotherapy resistance [373]B2b. On a finer scale, specific KRAS mutant alleles carry distinct prognoses: KRAS G12R is enriched in node-negative, early-stage disease with improved survival, while KRAS G12D is associated with increased EMT signaling and distant recurrence [260]B3b.
Machine learning and composite scores
Multivariable machine-learning models outperform single biomarkers. A random survival forest model incorporating age, CA 19-9, CRP, NLR, total protein, and metastatic status achieved a concordance index of 0.71, exceeding the AJCC stage-based model (0.62) [248]C4. Deep-learning-derived sarcopenia, measured by the abdominal muscle-to-bone ratio (MBR) on routine CT, predicts survival independently of performance status: low MBR carries an HR of 1.79 (95% CI 1.31-2.48) in advanced PDAC [246]C4. The Modified Glasgow Prognostic Score (mGPS), based on CRP and albumin, also stratifies cachectic patients for the likelihood of benefit from anamorelin [543]B2b[538]B2a.
Long-term sequelae and recurrence risk
Even after curative-intent resection, the recurrence rate is 70-80%, most often as distant metastases within 18-24 months [551]D5. Long-term survivors (>5 years from diagnosis) constitute only 7-9% of resected patients and often experience persistent fatigue, pain, and anxiety [122]D5[228]B2b. Quality-of-life assessment using EORTC QLQ-C30 shows that global health status declines significantly during chemotherapy but may stabilize in long-term survivors [228]B2b[522]A1b.
Pearl: The strongest independent predictors of survival in PDAC, resectability, performance status, CA 19-9 response, GATA6-based molecular subtype, and KRAS G12D versus G12R genotype, should be integrated into routine clinical prognostication and trial stratification [10]A1a[260]B3b[369]B2b[441]A1b[506]B2b.
| Factor | Favorable Prognosis | Unfavorable Prognosis |
|---|---|---|
| Stage & Resectability | Stage I, R0 resection, N0 | Stage IV, R1/R2, N1/N2 [553]D5 |
| CA 19-9 dynamics | Normalization post-op; >50% decline on therapy | Rise on therapy; post-op >90 U/mL [312]B3b[344]A1b |
| Performance status | ECOG PS 0-1 | ECOG PS ≥2 [534]B2c |
| NLR | <3-5 (variable cut-offs) | Elevated (>3-5), HR ~1.53 [10]A1a |
| VTE | Absent | Present at diagnosis (HR 1.62) [540]B2b |
| Sarcopenia (MBR) | Preserved muscle | Low MBR (HR 1.79) [246]C4 |
| Molecular subtype | Classical (GATA6-high) | Basal-like (HMGA2-high) [369]B2b[373]B2b[506]B2b |
| KRAS allele | G12R | G12D [260]B3b |
Special Populations
- ▸Older adults benefit from standard chemotherapy regimens but often require dose attenuation and comprehensive geriatric assessment to manage comorbidities and polypharmacy.
- ▸Pancreatic cancer in pregnancy is rare; contrast-enhanced MRI is the preferred staging modality, and chemotherapy is contraindicated in the first trimester.
- ▸Immunocompromised patients need infection prophylaxis, growth factor support, and careful monitoring of immunosuppressant levels during treatment.
Older adults account for over 70% of pancreatic cancer deaths yet remain underrepresented in clinical trials, limiting the evidence base for their [436]D5. Each special population, elderly, pregnant, pediatric, and immunocompromised, requires distinct diagnostic and therapeutic modifications that balance efficacy against unique risks.
Elderly Patients
Age alone should not preclude aggressive therapy, but physiological reserve, comorbidity burden, and polypharmacy demand individualized planning. In the NAPOLI 3 subgroup analysis, patients aged ≥70 years derived similar overall survival benefit from NALIRIFOX compared with younger patients, though with higher rates of grade ≥3 fatigue and diarrhea [562]A1b. For fit older adults ( 0-1, no significant organ dysfunction), standard-dose mFOLFIRINOX or / is appropriate, but dose attenuation is often necessary. A common strategy is to start at 75% of the full dose for the first cycle and escalate if tolerated [568]D5. Gemcitabine monotherapy remains a reasonable option for frail patients, with a median survival of 6-7 months and favorable toxicity profile [568]D5. Renal function declines with age; for S-1, a dosage formula based on creatinine clearance and body surface area can reduce toxicity without compromising efficacy [532]B2b. Comorbidity interactions are critical: pre-existing neuropathy from diabetes may worsen with , and cardiac disease increases risk of fluorouracil-induced ischemia. A (CGA) should guide treatment decisions rather than chronological age alone.
Pregnancy
Pancreatic cancer during pregnancy is exceedingly rare, with fewer than 50 cases reported. Presentation often mimics pregnancy-related symptoms (nausea, epigastric discomfort), leading to diagnostic delays. When suspected, contrast-enhanced MRI is preferred over CT to avoid fetal radiation exposure. Staging should include ultrasound and MRI without gadolinium if possible. Treatment depends on gestational age and tumor stage. In the first trimester, chemotherapy is contraindicated due to teratogenic risk (fluorouracil and gemcitabine are FDA Category D). For locally advanced or metastatic disease diagnosed after 14 weeks, neoadjuvant chemotherapy with gemcitabine-based regimens has been used with careful fetal monitoring. Delivery planning is essential: if the cancer is resectable, cesarean section at 32-34 weeks followed by immediate pancreatectomy may be considered. is contraindicated during chemotherapy and for at least 3 months after the last cycle due to drug excretion in breast milk. Multidisciplinary coordination among oncology, maternal-fetal medicine, and neonatology is mandatory.
Pediatric Patients
Pancreatic ductal adenocarcinoma in children is extraordinarily rare, with an incidence of <0.5 per million. Most pediatric pancreatic malignancies are pancreatoblastoma or solid pseudopapillary neoplasms, which have distinct biology and better prognosis. When PDAC does occur in adolescents, it is often associated with hereditary cancer syndromes such as Peutz-Jeghers syndrome, familial atypical multiple mole (FAMMM), or . Management is extrapolated from adult protocols, but dose adjustments are required: chemotherapy doses are calculated per body surface area (BSA) with a maximum adult dose cap. The developmental impact of treatment, including growth delay, gonadal toxicity, and secondary malignancies, must be addressed. Fertility preservation (sperm banking, oocyte cryopreservation) should be offered before initiating therapy. Long-term survivorship care includes monitoring for late effects such as cardiomyopathy from anthracyclines (if used) and neurocognitive deficits.
Immunocompromised Patients
Patients with HIV, solid organ transplant, or primary immunodeficiencies face increased risks of infection and reduced tolerance to myelosuppressive therapy. Before starting chemotherapy, CD4 count should be ≥200 cells/μL for HIV patients, and antiretroviral therapy should be optimized to avoid drug interactions (e.g., protease inhibitors increase toxicity). For transplant recipients, immunosuppressant levels ( , ) require close monitoring as chemotherapy can alter their metabolism. Growth factor support with G-CSF (filgrastim 5 μg/kg/day) is recommended as primary prophylaxis to reduce febrile neutropenia risk. Dose reductions of 20-25% for gemcitabine and nab- are often employed in the first cycle, with escalation based on tolerance. Live vaccines are contraindicated during treatment. The prognosis in immunocompromised patients is generally worse due to higher infection-related mortality and limited ability to deliver full-dose therapy, but case series show that selected patients can achieve similar response rates to the immunocompetent population.
Pearl: Special populations require proactive dose modification, comorbidity management, and multidisciplinary coordination; chronological age alone should not deny fit older patients effective therapy, and pregnancy-associated pancreatic cancer demands careful timing of chemotherapy and delivery to optimize maternal and fetal outcomes.
References
- [1]
Pelucchi C, La Vecchia C, Bosetti C et al.. “Exposure to acrylamide and human cancer--a review and meta-analysis of epidemiologic studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21239401 ↗
L1SR_OBSCited in: Definition and Epidemiology - [2]
Philip PA, Mooney M, Jaffe D et al.. “Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858397 ↗
L5TRIAL_NONRANDOMCited in: Definition and Epidemiology, Clinical Presentation, Staging - [3]
Moore MJ, Goldstein D, Hamm J et al.. “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17452677 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations - [4]
Chen IM, Johansen JS, Theile S et al.. “Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40354592 ↗
L1RCTCited in: Definition and Epidemiology, Clinical Presentation - [5]
Qin S, Li J, Bai Y et al.. “Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37647576 ↗
L1RCTCited in: Definition and Epidemiology - [6]
Willems RAL, van Diepen AE, Dekker EN et al.. “Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41610374 ↗
L1RCTCited in: Definition and Epidemiology - [7]
Chabot JA, Tsai WY, Fine RL et al.. “Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19687327 ↗
L3RCTCited in: Definition and Epidemiology - [8]
Chacón-Ovejero B, Pacheco-Barcia V, Palka-Kotlowska M et al.. “Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.” Cancer treatment reviews (2026). PMID: 42361440 ↗
L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention - [9]
Rebelatto TF, Falavigna M, Pozzari M et al.. “Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.” Cancer treatment reviews (2019). PMID: 31542591 ↗
L1SR_OBSCited in: Definition and Epidemiology - [10]
Mei Z, Shi L, Wang B et al.. “Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.” Cancer treatment reviews (2017). PMID: 28602879 ↗
L1SR_OBSCited in: Definition and Epidemiology, Prognosis and Prognostic Factors - [11]
Yazgan SC, Yekedüz E, Akkuş E et al.. “Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.” ESMO open (2025). PMID: 41027069 ↗
L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview - [12]
Yamada A, Komaki Y, Komaki F et al.. “Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.” The Lancet. Oncology (2018). PMID: 29706374 ↗
L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Prognosis and Prognostic Factors - [13]
Conroy T, Hammel P, Hebbar M et al.. “FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.” The New England journal of medicine (2018). PMID: 30575490 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations - [14]
Golan T, Hammel P, Reni M et al.. “Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.” The New England journal of medicine (2019). PMID: 31157963 ↗
L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview, Prognosis and Prognostic Factors, Special Populations - [15]
Holman RR, Bethel MA, Mentz RJ et al.. “Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2017). PMID: 28910237 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, Special Populations - [16]
Moore MJ, Goldstein D, Hamm J et al.. “Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37847995 ↗
L1TRIAL_NONRANDOMCited in: Definition and Epidemiology - [17]
Park W, Kasi A, Spira AI et al.. “Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.” The New England journal of medicine (2026). PMID: 41879829 ↗
L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Staging, Prognosis and Prognostic Factors - [18]
Park JH, Hong JY, Han K et al.. “Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41576296 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention - [19]
Genkinger JM, Wang M, Li R et al.. “Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24631943 ↗
L2REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention - [20]
Casolino R, Braconi C, Malleo G et al.. “Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33248227 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [21]
Genkinger JM, Kitahara CM, Bernstein L et al.. “Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26347100 ↗
L2REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [22]
Park HS, Kang B, Chon HJ et al.. “Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).” ESMO open (2021). PMID: 33578192 ↗
L3COHORTCited in: Definition and Epidemiology, Special Populations - [23]
Ullman NA, Burchard PR, Dunne RF et al.. “Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35839445 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview - [24]
Cardillo N, Seible DM, Fero KE et al.. “Clinical Impact of Local Progression in Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29891522 ↗
L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations - [25]
Ellsworth SG, Abdelhakiem M, Elgohari B et al.. “Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRT.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40505682 ↗
L4OTHERCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations - [26]
Sarkar RR, Fero KE, Seible DM et al.. “A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085756 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations - [27]
Schwartz NRM, Matrisian LM, Shrader EE et al.. “Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34153945 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [28]
Harris JP, Kashyap M, Humphreys JN et al.. “Longitudinal Analysis of Mental Disorder Burden Among Elderly Patients With Gastrointestinal Malignancies.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33401234 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [29]
Ko AH, Crane CH. “Radiation therapy in operable and locally advanced pancreatic cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20876542 ↗
L5OTHERCited in: Definition and Epidemiology - [30]
Cole AP, Lu C, Krimphove MJ et al.. “Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31487683 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [31]
Mokdad AA, Minter RM, Yopp AC et al.. “Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30545994 ↗
L2OTHERCited in: Definition and Epidemiology - [32]
Bockorny B, Macarulla T, Semenisty V et al.. “Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34253578 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology - [33]
Dușe TA, Ciocan A, Tiburca DE et al.. “Neoadjuvant Treatment Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356062 ↗
L1SR_MA_RCTCited in: Definition and Epidemiology, Management Overview - [34]
Yang F, Jin C, Jiang Y et al.. “Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.” Cancer treatment reviews (2011). PMID: 21330062 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation - [35]
Sabater L, Muñoz E, Roselló S et al.. “Borderline resectable pancreatic cancer. Challenges and controversies.” Cancer treatment reviews (2018). PMID: 29957372 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview - [36]
Yang F, Jin C, Subedi S et al.. “Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment.” Cancer treatment reviews (2012). PMID: 22655679 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview - [37]
Partelli S, Sclafani F, Barbu ST et al.. “European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer.” Cancer treatment reviews (2021). PMID: 34238640 ↗
L1REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview - [38]
Gallo M, Ruggeri RM, Muscogiuri G et al.. “Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?” Cancer treatment reviews (2018). PMID: 29746922 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Prognosis and Prognostic Factors - [39]
Al-Shaheri FN, Alhamdani MSS, Bauer AS et al.. “Blood biomarkers for differential diagnosis and early detection of pancreatic cancer.” Cancer treatment reviews (2021). PMID: 33865174 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers - [40]
Chiaravalli M, Reni M, O'Reilly EM. “Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.” Cancer treatment reviews (2017). PMID: 28869888 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview - [41]
Taieb J, Abdallah R. “How I treat pancreatic cancer.” ESMO open (2020). PMID: 32817138 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Imaging, Management Overview - [42]
Gallo M, Adinolfi V, Morviducci L et al.. “Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.” ESMO open (2021). PMID: 34020401 ↗
L1REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [43]
Barreto SG, Windsor JA. “Justifying vein resection with pancreatoduodenectomy.” The Lancet. Oncology (2016). PMID: 26972858 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors - [44]
Pannala R, Basu A, Petersen GM et al.. “New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer.” The Lancet. Oncology (2009). PMID: 19111249 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Imaging - [45]
Ribeiro T, Rebelo P, Rangelova E et al.. “Impact of cytoreductive surgery with HIPEC in the treatment of pancreatic cancer with peritoneal carcinomatosis: A systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42229165 ↗
L4SR_OBSCited in: Definition and Epidemiology, Clinical Presentation - [46]
Price CA, Cooke D, Mold F et al.. “Quantifying Weight Loss Prior to Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis.” Cancer medicine (2026). PMID: 42219540 ↗
L2SR_OBSCited in: Definition and Epidemiology, Clinical Presentation - [47]
Halbrook CJ, Lyssiotis CA. “Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.” Cancer cell (2017). PMID: 28073003 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Imaging - [48]
Santucci C, Mignozzi S, Levi F et al.. “European cancer mortality predictions for the year 2025 with focus on breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40074664 ↗
L2OTHERCited in: Definition and Epidemiology, Special Populations - [49]
Santucci C, Mignozzi S, Levi F et al.. “European cancer mortality predictions for the year 2026: the levelling of female lung cancer mortality.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41554652 ↗
L2OTHERCited in: Definition and Epidemiology, Special Populations - [50]
Malvezzi M, Santucci C, Boffetta P et al.. “European cancer mortality predictions for the year 2023 with focus on lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 36882139 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation - [51]
Dalmartello M, La Vecchia C, Bertuccio P et al.. “European cancer mortality predictions for the year 2022 with focus on ovarian cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35090748 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation - [52]
Santucci C, Mignozzi S, Malvezzi M et al.. “European cancer mortality predictions for the year 2024 with focus on colorectal cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38286716 ↗
L2OTHERCited in: Definition and Epidemiology - [53]
Carioli G, La Vecchia C, Bertuccio P et al.. “Cancer mortality predictions for 2017 in Latin America.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28911064 ↗
L2OTHERCited in: Definition and Epidemiology - [54]
Seyyedsalehi MS, Ciaccio L, Marra RF et al.. “Cadmium Exposure and Risk of Pancreatic Cancer: A Systematic Review and Meta-Analysis.” La Medicina del lavoro (2026). PMID: 42340218 ↗
L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention - [55]
Veenstra CM, Abrahamse P, Hamilton AS et al.. “Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40020204 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation - [56]
Borazanci E, Dang CV, Robey RW et al.. “Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28373361 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [57]
Larghi A, Verna EC, Lecca PG et al.. “Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19276278 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention - [58]
Hidalgo M, Von Hoff DD. “Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22896691 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [59]
Peretti U, Cavaliere A, Niger M et al.. “Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.” ESMO open (2021). PMID: 33399070 ↗
L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations - [60]
Yang S, Yeoh KW, Wong MC et al.. “Disparities of birth cohort effects on pancreatic cancer incidence between the United States and urban China.” ESMO open (2021). PMID: 34416471 ↗
L2OTHERCited in: Definition and Epidemiology - [61]
Trovato G, Rossini D, Guidolin A et al.. “Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis.” ESMO open (2025). PMID: 41205353 ↗
L2OTHERCited in: Definition and Epidemiology - [62]
Bruno W, Dalmasso B, Barile M et al.. “Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup.” ESMO open (2022). PMID: 35777164 ↗
L2OTHERCited in: Definition and Epidemiology - [63]
Hoberstorfer T, Spielvogel CP, Englisch C et al.. “Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study.” ESMO open (2026). PMID: 42202491 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [64]
Zarkavelis G, Kotoula V, Kolliou GA et al.. “Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG).” ESMO open (2019). PMID: 31673425 ↗
L4OTHERCited in: Definition and Epidemiology - [65]
McPhail S, Swann R, Johnson SA et al.. “Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study.” The Lancet. Oncology (2022). PMID: 35397210 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Prognosis and Prognostic Factors - [66]
Rashid T, Bennett JE, Muller DC et al.. “Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.” The Lancet. Oncology (2023). PMID: 38096890 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [67]
O'Reilly EM, Wainberg ZA, Hendifar AE et al.. “Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.” The New England journal of medicine (2026). PMID: 42223072 ↗
L1OTHERCited in: Definition and Epidemiology - [68]
Song BG, Kim TS, Kim BS et al.. “Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.” Diabetes & metabolism (2026). PMID: 42349715 ↗
L2COHORTCited in: Definition and Epidemiology - [69]
Park JH, Hong JY, Shen JJ et al.. “Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.” Mayo Clinic proceedings (2026). PMID: 42349652 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [70]
Miyaishi K, Kawamoto S, Yamamoto K et al.. “Preoperative Blood Augmentation in Jehovah's Witness Patients Undergoing Transfusion-Free Surgery for Gastrointestinal or Hepato-biliary-pancreatic Cancer: Retrospective Cohort Study.” Anesthesia and analgesia (2026). PMID: 42302296 ↗
L2COHORTCited in: Definition and Epidemiology - [71]
Ludvigsson JF, Sun J, Yuan C et al.. “Risk of pancreatic cancer associated with precursor lesions in individuals and first-degree relatives: a nationwide cohort study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 42297317 ↗
L2COHORTCited in: Definition and Epidemiology - [72]
Ilbekova K, Ibrayeva D, Saifulina E et al.. “Digestive Tract Cancer: A Retrospective Study of the Epidemiological Profile of Populations Exposed and Not Exposed to Uranium Contamination in North Kazakhstan (2014-2023).” Journal of clinical medicine (2026). PMID: 42279191 ↗
L2COHORTCited in: Definition and Epidemiology, Clinical Presentation - [73]
Blackford AL, Canto MI, Dbouk M et al.. “Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.” JAMA oncology (2024). PMID: 38959011 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors, Special Populations - [74]
Meng Y, Wu F, Kwak S et al.. “Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer.” JAMA oncology (2025). PMID: 40965868 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations - [75]
Reyngold M, Schoenfeld JD, O'Reilly EM et al.. “Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy.” JAMA oncology (2025). PMID: 40208620 ↗
L4OTHERCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations - [76]
Yuan C, Babic A, Khalaf N et al.. “Diabetes, Weight Change, and Pancreatic Cancer Risk.” JAMA oncology (2020). PMID: 32789511 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations - [77]
Mavromatis LA, Zlatanic V, Agarunov E et al.. “Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer.” JAMA oncology (2026). PMID: 41885821 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Special Populations - [78]
Ding J, Edelmann D, Carlsson SV et al.. “Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer.” JAMA oncology (2026). PMID: 42133339 ↗
L2OTHERCited in: Definition and Epidemiology - [79]
Tao J, Pfeiffer RM, Ahmed S et al.. “Cancer Risk in Solid Organ Transplant Recipients With a Pretransplant Cancer History.” JAMA oncology (2026). PMID: 41817522 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [80]
Burus T, Lei F, Huang B et al.. “Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic.” JAMA oncology (2024). PMID: 38386344 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [81]
van Roessel S, van Veldhuisen E, Klompmaker S et al.. “Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.” JAMA oncology (2020). PMID: 32910170 ↗
L3OTHERCited in: Definition and Epidemiology, Management Overview - [82]
Reyngold M, O'Reilly EM, Varghese AM et al.. “Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer.” JAMA oncology (2021). PMID: 33704353 ↗
L3OTHERCited in: Definition and Epidemiology, Management Overview - [83]
Carpenter ES, Elhossiny AM, Kadiyala P et al.. “Analysis of Donor Pancreata Defines the Transcriptomic Signature and Microenvironment of Early Neoplastic Lesions.” Cancer discovery (2023). PMID: 37021392 ↗
L4OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology - [84]
Kurz E, Hirsch CA, Dalton T et al.. “Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer.” Cancer cell (2022). PMID: 35660135 ↗
L5OTHERCited in: Definition and Epidemiology, Management Overview - [85]
Xie X, Xia W, Li Z et al.. “Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models.” Cancer cell (2007). PMID: 17613436 ↗
L5OTHERCited in: Definition and Epidemiology - [86]
Yokoyama S, Hamada T, Higashi M et al.. “Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31992588 ↗
L3OTHERCited in: Definition and Epidemiology, Imaging, Staging, Prognosis and Prognostic Factors - [87]
Jonna S, Feldman RA, Swensen J et al.. “Detection of NRG1 Gene Fusions in Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30988082 ↗
L3OTHERCited in: Definition and Epidemiology - [88]
Whatcott CJ, Diep CH, Jiang P et al.. “Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25695692 ↗
L3OTHERCited in: Definition and Epidemiology - [89]
Luo H, England CG, Shi S et al.. “Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27026197 ↗
L5OTHERCited in: Definition and Epidemiology, Imaging - [90]
Lu S, Zhang Z, Du P et al.. “A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31767564 ↗
L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [91]
Tsang ES, Topham JT, Karasinska JM et al.. “Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32958704 ↗
L3OTHERCited in: Definition and Epidemiology - [92]
Daly MB, Pal T, Berry MP et al.. “Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33406487 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Management Overview - [93]
Daly MB, Pilarski R, Yurgelun MB et al.. “NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32259785 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Management Overview - [94]
Stoffel EM, McKernin SE, Brand R et al.. “Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30457921 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [95]
Locker GY, Hamilton S, Harris J et al.. “ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17060676 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Imaging, Molecular Diagnostics and Biomarkers - [96]
Park JH, Hong JY, Shen JJ et al.. “Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37935099 ↗
L2COHORTCited in: Risk Factors and Prevention - [97]
Maisonneuve P, Amar S, Lowenfels AB. “Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28453689 ↗
L1SR_OBSCited in: Risk Factors and Prevention - [98]
Turati F, Galeone C, Edefonti V et al.. “A meta-analysis of coffee consumption and pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21746805 ↗
L1SR_OBSCited in: Risk Factors and Prevention - [99]
Aune D, Greenwood DC, Chan DS et al.. “Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21890910 ↗
L1SR_OBSCited in: Risk Factors and Prevention, Clinical Presentation - [100]
Casolino R, Paiella S, Azzolina D et al.. “Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34197182 ↗
L1SR_OBSCited in: Risk Factors and Prevention - [101]
Leonhardt CS, Stamm T, Hank T et al.. “Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.” ESMO open (2023). PMID: 37988953 ↗
L4SR_OBSCited in: Risk Factors and Prevention, Management Overview - [102]
Middleton G, Silcocks P, Cox T et al.. “Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.” The Lancet. Oncology (2014). PMID: 24954781 ↗
L1RCTCited in: Risk Factors and Prevention, Clinical Presentation - [103]
Pearson C, Jones DA, Baily G et al.. “Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.” The Lancet. Oncology (2026). PMID: 41713471 ↗
L3COHORTCited in: Risk Factors and Prevention, Clinical Presentation, Staging - [104]
van 't Land FR, Willemsen M, Bezemer K et al.. “Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38950309 ↗
L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Management Overview, Special Populations - [105]
Ott PA, Bang YJ, Piha-Paul SA et al.. “T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30557521 ↗
L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [106]
Bidoli E, Pelucchi C, Zucchetto A et al.. “Fiber intake and pancreatic cancer risk: a case-control study.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21460379 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention, Special Populations - [107]
Waterhouse M, Risch HA, Bosetti C et al.. “Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25977560 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention, Clinical Presentation, Special Populations - [108]
Pelucchi C, Rosato V, Bracci PM et al.. “Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case-Control Consortium (PanC4).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27836886 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention - [109]
Duell EJ, Lucenteforte E, Olson SH et al.. “Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22767586 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention - [110]
Lucenteforte E, La Vecchia C, Silverman D et al.. “Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21536662 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention - [111]
Sarno F, Tenorio J, Perea S et al.. “A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39540844 ↗
L1RCTCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Special Populations - [112]
Chantrill LA, Nagrial AM, Watson C et al.. “Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25896973 ↗
L4RCTCited in: Risk Factors and Prevention, Histopathology and Molecular Biology - [113]
Misek DE, Patwa TH, Lubman DM et al.. “Early detection and biomarkers in pancreatic cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 18053427 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers - [114]
Daly MB, Pilarski R, Axilbund JE et al.. “Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26850485 ↗
L1OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology - [115]
Zhao Y, Wang Z, Xu M et al.. “Chemoprophylaxis effect of EGCG on various digestive system diseases: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42359071 ↗
L5SR_OBSCited in: Risk Factors and Prevention - [116]
Yuan C, Kim J, Wang QL et al.. “The age-dependent association of risk factors with pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35398288 ↗
L2OTHERCited in: Risk Factors and Prevention - [117]
Dores GM, Curtis RE, van Leeuwen FE et al.. “Pancreatic cancer risk after treatment of Hodgkin lymphoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25185241 ↗
L3OTHERCited in: Risk Factors and Prevention, Special Populations - [118]
Stoop TF, Croce C, Ishida H et al.. “Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international multicentre retrospective study.” BJS open (2026). PMID: 42263216 ↗
L3COHORTCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview, Special Populations - [119]
Daniel F, Abdallah B, Chaitou AR et al.. “Association between postoperative Clostridioides difficile infection and outcomes following pancreatoduodenectomy for pancreatic cancer: a national cohort study.” Surgical endoscopy (2026). PMID: 42257924 ↗
L3COHORTCited in: Risk Factors and Prevention, Management Overview, Special Populations - [120]
Zhang A, Zhu X, Li Z et al.. “Type 2 Diabetes, Glycemic Traits and Overall Cancer Risk: A Large-Scale Prospective Cohort Study.” Cancer medicine (2026). PMID: 42144703 ↗
L2COHORTCited in: Risk Factors and Prevention - [121]
Ando Y, Dbouk M, Yoshida T et al.. “Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38457748 ↗
L3OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers - [122]
Heestand GM, Murphy JD, Lowy AM. “Approach to patients with pancreatic cancer without detectable metastases.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918279 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Prognosis and Prognostic Factors - [123]
Stoffel EM. “Screening in GI Cancers: The Role of Genetics.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918283 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers - [124]
Genkinger JM, Klein AP. “Why Is Earlier Detection, the Key to Reducing Pancreatic Cancer, So Challenging Despite Technological Advances?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40743485 ↗
L5OTHERCited in: Risk Factors and Prevention - [125]
Hassan MM, Li D, El-Deeb AS et al.. “Association between hepatitis B virus and pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18824707 ↗
L3OTHERCited in: Risk Factors and Prevention - [126]
Yuan C, Bao Y, Wu C et al.. “Prediagnostic body mass index and pancreatic cancer survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24145341 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation - [127]
Abdullah M, Zaheer A, Lodhi BA et al.. “Effectiveness of multidisciplinary team collaboration in focal pancreatic lesion management: a systematic review.” Abdominal radiology (New York) (2026). PMID: 42257900 ↗
L2SR_OBSCited in: Risk Factors and Prevention, Clinical Presentation, Imaging - [128]
Petrelli F, Dottorini L, Celotti A et al.. “Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.” Cancer treatment reviews (2026). PMID: 42341370 ↗
L2REVIEW_NARRATIVECited in: Risk Factors and Prevention - [129]
Custodio A, Puente J, Sastre J et al.. “Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.” Cancer treatment reviews (2009). PMID: 19758760 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Special Populations - [130]
Sideras K, Braat H, Kwekkeboom J et al.. “Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.” Cancer treatment reviews (2013). PMID: 24315741 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [131]
Mahmood U, Carrier E, Khan K. “Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm.” Cancer treatment reviews (2024). PMID: 38703592 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [132]
Berger JM, Alany A, Puhr R et al.. “Clinical risk factors for ascites in metastatic pancreatic cancer.” ESMO open (2023). PMID: 36989885 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview - [133]
Russo A, Incorvaia L, Capoluongo E et al.. “Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.” ESMO open (2022). PMID: 35597177 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview - [134]
Peacock HM, Tambuyzer T, Verdoodt F et al.. “Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis.” ESMO open (2021). PMID: 34474811 ↗
L2OTHERCited in: Risk Factors and Prevention - [135]
Huntley C, Torr B, Sud A et al.. “Utility of polygenic risk scores in UK cancer screening: a modelling analysis.” The Lancet. Oncology (2023). PMID: 37178708 ↗
L2REVIEW_NARRATIVECited in: Risk Factors and Prevention - [136]
Cheng HH, Shevach JW, Castro E et al.. “BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.” JAMA oncology (2024). PMID: 39052257 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview - [137]
Inamdar S, Slattery E, Bhalla R et al.. “Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort.” JAMA oncology (2016). PMID: 26513013 ↗
L2OTHERCited in: Risk Factors and Prevention, Prognosis and Prognostic Factors - [138]
Mano R, Tamir S, Kedar I et al.. “Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort.” JAMA oncology (2018). PMID: 29710070 ↗
L2OTHERCited in: Risk Factors and Prevention - [139]
Sang W, Zhou Y, Chen H et al.. “Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer.” Cancer discovery (2024). PMID: 37824278 ↗
L5OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview - [140]
Wang X, Wang H, Zhang M et al.. “Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer.” Cancer discovery (2026). PMID: 40982573 ↗
L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Molecular Diagnostics and Biomarkers, Special Populations - [141]
Zhou T, Yan J, Mao G et al.. “Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring.” Cancer discovery (2026). PMID: 41891402 ↗
L5OTHERCited in: Risk Factors and Prevention - [142]
Heining C, Horak P, Uhrig S et al.. “NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.” Cancer discovery (2018). PMID: 29802158 ↗
L4OTHERCited in: Risk Factors and Prevention, Prognosis and Prognostic Factors - [143]
Hegde S, Krisnawan VE, Herzog BH et al.. “Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.” Cancer cell (2020). PMID: 32183949 ↗
L5OTHERCited in: Risk Factors and Prevention, Management Overview - [144]
Zheng C, Fass JN, Shih YP et al.. “Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.” Cancer cell (2022). PMID: 35413272 ↗
L4OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology - [145]
Hayes TK, Neel NF, Hu C et al.. “Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.” Cancer cell (2015). PMID: 26725216 ↗
L5OTHERCited in: Risk Factors and Prevention - [146]
Tu YK, Liang YC, Wu YJ et al.. “The association between sodium-glucose cotransporter 2 inhibitor and risk of pancreatic cancer among patients with type 2 diabetes mellitus: A real-world cohort study.” Medicine (2026). PMID: 42332532 ↗
L2COHORTCited in: Risk Factors and Prevention, Management Overview - [147]
Anderko RR, Bowman AE, Murthy P et al.. “Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41342881 ↗
L4OTHERCited in: Risk Factors and Prevention - [148]
Zhang Y, Houchen CW, Li M. “Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35617521 ↗
L5OTHERCited in: Risk Factors and Prevention - [149]
Effenberger KE, Schroeder C, Hanssen A et al.. “Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29559560 ↗
L2OTHERCited in: Risk Factors and Prevention - [150]
Li D, Abbruzzese JL. “New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20647474 ↗
L5OTHERCited in: Risk Factors and Prevention, Clinical Presentation - [151]
Chu NJ, Armstrong TD, Jaffee EM. “Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25623216 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [152]
Alagesan B, Contino G, Guimaraes AR et al.. “Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25348516 ↗
L5OTHERCited in: Risk Factors and Prevention - [153]
Verna EC, Hwang C, Stevens PD et al.. “Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20876795 ↗
L2OTHERCited in: Risk Factors and Prevention - [154]
Chen H, Zhou W, Bian A et al.. “Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36374556 ↗
L5OTHERCited in: Risk Factors and Prevention - [155]
Delcuratolo MD, Cocomazzi G, Beccia V et al.. “The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.” Biomedicines (2026). PMID: 42351835 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [156]
Karnan S, Ota A, Hasan MN et al.. “Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells.” Cell death & disease (2026). PMID: 42336821 ↗
L5OTHERCited in: Risk Factors and Prevention - [157]
Grossman SA, Ellsworth S, Campian J et al.. “Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26483062 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors, Special Populations - [158]
Middleton G, Palmer DH, Greenhalf W et al.. “Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.” The Lancet. Oncology (2017). PMID: 28259610 ↗
L1RCTCited in: Histopathology and Molecular Biology, Staging - [159]
Hyung J, Lee H, Jin H et al.. “Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.” ESMO open (2022). PMID: 35576696 ↗
L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis - [160]
Tan HL, Zhao Y, Chua DW et al.. “Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials.” Surgery (2025). PMID: 41381268 ↗
L1SR_MA_RCTCited in: Histopathology and Molecular Biology - [161]
Liebs S, Nonnenmacher A, Klauschen F et al.. “Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature.” ESMO open (2019). PMID: 31555482 ↗
L4CASE_REPORTCited in: Histopathology and Molecular Biology - [162]
Scarlato E, Dusetti N, Melisi D. “Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities.” Cancer treatment reviews (2026). PMID: 41886796 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Clinical Presentation, Molecular Diagnostics and Biomarkers - [163]
Fraunhoffer N, Hammel P, Conroy T et al.. “Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38906254 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Management Overview, Special Populations - [164]
Nicolle R, Gayet O, Duconseil P et al.. “A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33188873 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [165]
Hendifar AE, Krishna V, Krishna V et al.. “Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41671529 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [166]
Guo JA, Hoffman HI, Weekes CD et al.. “Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33653818 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [167]
Carrizosa DR, Rothe M, Mangat PK et al.. “Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO precision oncology (2026). PMID: 41538762 ↗
L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology - [168]
Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2016). PMID: 27993569 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Staging - [169]
Bonù ML, Balduzzi J, Pedersoli G et al.. “Impact of Dosimetric Parameters on Tumor Control in Stereotactic Radiotherapy for Pancreatic Cancer: A Prospective Study on 104 Patients Treated with Simultaneous Integrated Protection (SIP).” Cancers (2025). PMID: 41300984 ↗
L2COHORTCited in: Histopathology and Molecular Biology - [170]
Flowers BM, Xu H, Mulligan AS et al.. “Cell of Origin Influences Pancreatic Cancer Subtype.” Cancer discovery (2021). PMID: 34009137 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [171]
Ben-Shmuel A, Scherz-Shouval R. “Keeping IPMNs in Check: A Novel Role for the Transcription Factor NKX6-2 in Preserving an Indolent Cell Identity in Pancreatic Cystic Lesions.” Cancer discovery (2023). PMID: 37539476 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [172]
Chen SH, Zhang Y, Van Horn RD et al.. “Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.” Cancer discovery (2016). PMID: 26732095 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [173]
Li J, Yuan S, Norgard RJ et al.. “Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.” Cancer discovery (2020). PMID: 33158848 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [174]
Chen MM, Gao Q, Ning H et al.. “Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer.” Cancer cell (2025). PMID: 40680743 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [175]
. “Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.” Cancer cell (2017). PMID: 28810144 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [176]
Di Chiaro P, Nacci L, Arco F et al.. “Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer.” Cancer cell (2024). PMID: 38518775 ↗
L4OTHERCited in: Histopathology and Molecular Biology - [177]
Connor AA, Denroche RE, Jang GH et al.. “Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.” Cancer cell (2019). PMID: 30686769 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers - [178]
Wang L, Heidt DG, Lee CJ et al.. “Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.” Cancer cell (2009). PMID: 19249679 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation - [179]
Facciorusso A, Bellocchi MCC, De Pretis N et al.. “Endoscopic Ultrasound-guided Fine-Needle Biopsy With End-Cutting Needles in Autoimmune Pancreatitis: A Systematic Review and Meta-Analysis.” DEN open (2025). PMID: 41195006 ↗
L1SR_OBSCited in: Histopathology and Molecular Biology - [180]
. “Recruited Nerves Supply Serine to Support Pancreatic Cancer Growth.” Cancer discovery (2020). PMID: 33188053 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [181]
Mota J, Ribeiro T, Conti Bellocchi MC et al.. “Endoscopic ultrasound through-the-needle biopsy of pancreatic cystic neoplasms: Update on indications, safety profile, and research directions.” Best practice & research. Clinical gastroenterology (2025). PMID: 42167851 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis - [182]
Wang J, Luo W, Zhang M et al.. “Artificial intelligence: Catalyzing a new era in pancreatic cancer cure.” Cancer letters (2026). PMID: 42081963 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [183]
Zhu Y, Ma K, Hao Q et al.. “The RNA methylation modification as an immunometabolic regulatory hub in pancreatic cancer: from mechanistic insights to clinical translation perspectives.” Molecular cancer (2026). PMID: 42021253 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [184]
Capurso G, Garajova I, Neuzillet C et al.. “Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41846177 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [185]
Di Martino M, Ministrini S, Tiberio G et al.. “Liver resection for noncolorectal liver metastases: the good, the bad, and the ugly.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2026). PMID: 41825768 ↗
L2REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [186]
D'Empaire Altimari DM, Bevere M, Espinet E et al.. “Molecular subtypes in pancreatic cancer: from academic promise to clinical reality.” Molecular cancer (2026). PMID: 41796340 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [187]
Loveless IM, Kemp SB, Hartway KM et al.. “Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39636224 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [188]
Lee JJ, Bernard V, Semaan A et al.. “Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34426439 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis - [189]
León-Letelier RA, Chen Y, Dou R et al.. “Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40184234 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Special Populations - [190]
Donahue TR, Tran LM, Hill R et al.. “Integrative survival-based molecular profiling of human pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22261810 ↗
L4OTHERCited in: Histopathology and Molecular Biology - [191]
Yu J, Li A, Hong SM et al.. “MicroRNA alterations of pancreatic intraepithelial neoplasias.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 22114139 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [192]
Liu M, Yang J, Zhang Y et al.. “ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29615456 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Staging - [193]
Dey P, Rachagani S, Chakraborty S et al.. “Overexpression of ecdysoneless in pancreatic cancer and its role in oncogenesis by regulating glycolysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22977192 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [194]
Kikuchi S, Honda K, Tsuda H et al.. “Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18765526 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [195]
Chida K, Kawazoe A, Suzuki T et al.. “Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35254400 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [196]
Li X, Truty MA, Kang Y et al.. “Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25336691 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [197]
Guo K, Cui J, Quan M et al.. “The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27449499 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [198]
Lee J, Condello S, Yakubov B et al.. “Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26041746 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [199]
Cui J, Shi M, Xie D et al.. “FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24634381 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [200]
Frisch A, Martin E, Cannon T et al.. “Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.” Current oncology (Toronto, Ont.) (2026). PMID: 41892176 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [201]
Cicala A, Dziadowicz SA, Westcott PMK. “A pancreatic intraepithelial neoplasia-Oramic view of early pancreatic cancer in 3D.” Trends in immunology (2026). PMID: 42265012 ↗
L4OTHERCited in: Histopathology and Molecular Biology - [202]
Li R, Xu X, Zhang W et al.. “Single-cell and spatial transcriptomic profiling reveals the expression characteristics of PTPRR in epithelial cells and its potential implications in pancreatic cancer metastasis.” Frontiers in immunology (2026). PMID: 42212130 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers - [203]
Powers J, Wei L, Cheung JCT et al.. “eIF4G2-Dependent Translation Restrains Pancreatic Cancer Progression.” Cancer research (2026). PMID: 42202060 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [204]
Tempero MA, Malafa MP, Al-Hawary M et al.. “Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33845462 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview - [205]
Tempero MA, Malafa MP, Al-Hawary M et al.. “Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784865 ↗
L1GUIDELINECited in: Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors - [206]
Tempero MA, Arnoletti JP, Behrman SW et al.. “Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 22679115 ↗
L1GUIDELINECited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors - [207]
Sohal DPS, Kennedy EB, Khorana A et al.. “Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29791286 ↗
L1GUIDELINECited in: Clinical Presentation - [208]
Neuzillet C, Bouché O, Tournigand C et al.. “Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38081120 ↗
L1RCTCited in: Clinical Presentation, Management Overview - [209]
Tai D, Conroy T, Lee JJX et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer.” ESMO open (2025). PMID: 41067164 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview - [210]
Suker M, Beumer BR, Sadot E et al.. “FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.” The Lancet. Oncology (2016). PMID: 27160474 ↗
L1SR_OBSCited in: Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors - [211]
Kempers MJ, Kuiper RP, Ockeloen CW et al.. “Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.” The Lancet. Oncology (2010). PMID: 21145788 ↗
L2COHORTCited in: Clinical Presentation - [212]
Groarke JD, Crawford J, Collins SM et al.. “Ponsegromab for the Treatment of Cancer Cachexia.” The New England journal of medicine (2024). PMID: 39282907 ↗
L1RCTCited in: Clinical Presentation, Management Overview, Special Populations - [213]
Al-Samkari H, Muñoz C, Geredeli Ç et al.. “Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.” The New England journal of medicine (2026). PMID: 41812193 ↗
L1RCTCited in: Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations - [214]
Cecchini M, Salem RR, Robert M et al.. “Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38900452 ↗
L4RCTCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations - [215]
Sohal DPS, Duong M, Ahmad SA et al.. “Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33475684 ↗
L1RCTCited in: Clinical Presentation, Management Overview - [216]
Lawrence YR, Miszczyk M, Dawson LA et al.. “Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 39029483 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations - [217]
Lakhani NJ, Chow LQM, Gainor JF et al.. “Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.” The Lancet. Oncology (2021). PMID: 34793719 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations - [218]
Alistar A, Morris BB, Desnoyer R et al.. “Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.” The Lancet. Oncology (2017). PMID: 28495639 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation - [219]
Schram AM, Goto K, Kim DW et al.. “Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.” The New England journal of medicine (2025). PMID: 39908431 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations - [220]
Chen L, Davelaar J, Gaddam S et al.. “Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36395704 ↗
L4CASE_REPORTCited in: Clinical Presentation, Special Populations - [221]
McPhail S, Barclay ME, Johnson SA et al.. “Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study.” The Lancet. Oncology (2024). PMID: 38423048 ↗
L2SR_OBSCited in: Clinical Presentation, Special Populations - [222]
Gilbert JW, Wolpin B, Clancy T et al.. “Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28407088 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Management Overview - [223]
Kleger A, Perkhofer L, Seufferlein T. “Smarter drugs emerging in pancreatic cancer therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24631947 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview, Special Populations - [224]
Duffy MJ, Sturgeon C, Lamerz R et al.. “Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19690057 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers - [225]
Bosetti C, Rosato V, Li D et al.. “Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25057164 ↗
L3CASE_CONTROLCited in: Clinical Presentation - [226]
Zogopoulos G, Haimi I, Sanoba SA et al.. “The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38626807 ↗
L2OTHERCited in: Clinical Presentation, Imaging - [227]
Al-Hawary M. “Role of Imaging in Diagnosing and Staging Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27226513 ↗
L5OTHERCited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors - [228]
Seelen LWF, Augustinus S, Stoop TF et al.. “Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 39970867 ↗
L2OTHERCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors, Special Populations - [229]
Tempero M. “Active Systemic Treatment of Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28515255 ↗
L5OTHERCited in: Clinical Presentation, Management Overview - [230]
Boucher Y, Posada JM, Subudhi S et al.. “Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36749873 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation - [231]
De Dosso S, Siebenhüner AR, Winder T et al.. “Treatment landscape of metastatic pancreatic cancer.” Cancer treatment reviews (2021). PMID: 33812339 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview - [232]
Pliarchopoulou K, Pectasides D. “Pancreatic cancer: current and future treatment strategies.” Cancer treatment reviews (2009). PMID: 19328630 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [233]
Prades J, Arnold D, Brunner T et al.. “Bratislava Statement: consensus recommendations for improving pancreatic cancer care.” ESMO open (2020). PMID: 33188052 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [234]
Taieb J, Prager GW, Melisi D et al.. “First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.” ESMO open (2020). PMID: 31958291 ↗
L4REVIEW_NARRATIVECited in: Clinical Presentation - [235]
Rangelova E, Stoop TF, van Ramshorst TME et al.. “The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39814200 ↗
L4OTHERCited in: Clinical Presentation, Management Overview, Special Populations - [236]
Du W, Zhou Y, Huang H et al.. “Diagnostic value of EUS-guided tissue acquisition in suspected autoimmune pancreatitis: A 15-year single-center retrospective study.” Endoscopic ultrasound (2026). PMID: 42292789 ↗
L4COHORTCited in: Clinical Presentation - [237]
Yang R, Sun Y, An R et al.. “Head to head comparison of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT in the diagnosis and staging of pancreatic cancer: a prospective study.” EJNMMI research (2026). PMID: 42249240 ↗
L2COHORTCited in: Clinical Presentation, Imaging - [238]
Wexler RP. “The Liver We Share.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 42048617 ↗
L5OTHERCited in: Clinical Presentation - [239]
Yuan C, Morales-Oyarvide V, Babic A et al.. “Cigarette Smoking and Pancreatic Cancer Survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28358654 ↗
L2OTHERCited in: Clinical Presentation - [240]
Yuan C, Qian ZR, Babic A et al.. “Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27325858 ↗
L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers - [241]
Yuan C, Rubinson DA, Qian ZR et al.. “Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25403204 ↗
L2OTHERCited in: Clinical Presentation - [242]
Wei D, Wang L, Liu Y et al.. “CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40757874 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview - [243]
Kiehl F, De Lazzari N, Beller R et al.. “High-Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls: Implications for Cancer Care.” Cancer medicine (2026). PMID: 42233178 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Special Populations - [244]
Mizuma M, Hirakawa S, Tachimori H et al.. “Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study using the Japan Pancreatic Cancer Registry.” Pancreas (2026). PMID: 42348544 ↗
L4COHORTCited in: Clinical Presentation - [245]
Ikushima H, Watanabe K, Shinozaki-Ushiku A et al.. “Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data.” ESMO open (2025). PMID: 40138743 ↗
L4OTHERCited in: Clinical Presentation, Special Populations - [246]
Keyl J, Bucher A, Jungmann F et al.. “Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study.” ESMO open (2024). PMID: 38194881 ↗
L4OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors - [247]
Berger JM, Alany A, Berchtold L et al.. “Prognosticators of survival in patients with metastatic pancreatic cancer and ascites.” ESMO open (2023). PMID: 37977000 ↗
L4OTHERCited in: Clinical Presentation, Management Overview - [248]
Keyl J, Kasper S, Wiesweg M et al.. “Multimodal survival prediction in advanced pancreatic cancer using machine learning.” ESMO open (2022). PMID: 35988455 ↗
L4OTHERCited in: Clinical Presentation, Imaging, Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [249]
Reissig TM, Tzianopoulos I, Liffers ST et al.. “Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.” ESMO open (2023). PMID: 37148593 ↗
L4OTHERCited in: Clinical Presentation, Management Overview - [250]
Pishvaian MJ, Blais EM, Brody JR et al.. “Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.” The Lancet. Oncology (2020). PMID: 32135080 ↗
L4OTHERCited in: Clinical Presentation, Management Overview, Special Populations - [251]
Zeng C, Bastarache LA, Tao R et al.. “Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases.” JAMA oncology (2022). PMID: 35446370 ↗
L2OTHERCited in: Clinical Presentation - [252]
O'Connor CA, Harrold E, Lin D et al.. “Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.” JAMA oncology (2024). PMID: 39235819 ↗
L3OTHERCited in: Clinical Presentation, Management Overview, Special Populations - [253]
Unger JM, Fisch MJ, Jones SMW et al.. “Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy.” JAMA oncology (2026). PMID: 41452615 ↗
L2OTHERCited in: Clinical Presentation, Management Overview - [254]
Fonteneau G, Redding A, Hoag-Lee H et al.. “Stress Granules Determine the Development of Obesity-Associated Pancreatic Cancer.” Cancer discovery (2022). PMID: 35674408 ↗
L5OTHERCited in: Clinical Presentation - [255]
Mullen KM, Hong J, Attiyeh MA et al.. “The Evolutionary Forest of Pancreatic Cancer.” Cancer discovery (2025). PMID: 39378050 ↗
L3OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [256]
Tsui WHA, Lo YMD. “Checking Up on the King of Cancers.” Cancer discovery (2026). PMID: 41521773 ↗
L5OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [257]
Incio J, Liu H, Suboj P et al.. “Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.” Cancer discovery (2016). PMID: 27246539 ↗
L5OTHERCited in: Clinical Presentation - [258]
Lee KE, Spata M, Bayne LJ et al.. “Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.” Cancer discovery (2015). PMID: 26715642 ↗
L5OTHERCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors - [259]
Liu M, Ren Y, Zhou Z et al.. “The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.” Cancer cell (2024). PMID: 38608702 ↗
L5OTHERCited in: Clinical Presentation - [260]
McIntyre CA, Grimont A, Park J et al.. “Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.” Cancer cell (2024). PMID: 39214094 ↗
L3OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors, Special Populations - [261]
Kerzel T, Giacca G, Beretta S et al.. “In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases.” Cancer cell (2023). PMID: 37863068 ↗
L5OTHERCited in: Clinical Presentation, Management Overview - [262]
Kureshi CTS, Walsh MJ, Kureshi R et al.. “Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer.” Cancer cell (2026). PMID: 42102812 ↗
L5OTHERCited in: Clinical Presentation - [263]
Von Hoff DD, Korn R, Mousses S. “Pancreatic cancer--could it be that simple? A different context of vulnerability.” Cancer cell (2009). PMID: 19573807 ↗
L5OTHERCited in: Clinical Presentation, Imaging - [264]
Rashid NU, Peng XL, Jin C et al.. “Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31754050 ↗
L3OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [265]
Zhao T, Jiang T, Li X et al.. “Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37819952 ↗
L5OTHERCited in: Clinical Presentation, Management Overview - [266]
Korc M. “Pancreatic cancer-associated diabetes is an "exosomopathy".” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25645860 ↗
L5OTHERCited in: Clinical Presentation - [267]
Wang H, Maitra A, Wang H. “Obesity, Intrapancreatic Fatty Infiltration, and Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25995340 ↗
L5OTHERCited in: Clinical Presentation - [268]
Romero JM, Grünwald B, Jang GH et al.. “A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31964786 ↗
L3OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis - [269]
Staal B, Liu Y, Barnett D et al.. “The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30617132 ↗
L3OTHERCited in: Clinical Presentation - [270]
Cazes A, Betancourt O, Esparza E et al.. “A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33451980 ↗
L5OTHERCited in: Clinical Presentation - [271]
Chauffert B, Mornex F, Bonnetain F et al.. “Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18467316 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis, Staging - [272]
Sinn M, Sinn BV, Striefler JK et al.. “SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24562449 ↗
L2RCTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [273]
Cuneo KC, Morgan MA, Sahai V et al.. “Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31398082 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [274]
Jabbar KS, Arike L, Verbeke CS et al.. “Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29166170 ↗
L3TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [275]
Wang Y, Cuggia A, Pacis A et al.. “Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34416708 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis - [276]
Javle M, Shacham-Shmueli E, Xiao L et al.. “Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.” JAMA oncology (2021). PMID: 33662100 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Special Populations - [277]
Kanwar N, Seyi AB, Tan N et al.. “From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671451 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [278]
Castillo J, Bernard V, San Lucas FA et al.. “Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29045505 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [279]
Lee B, Lipton L, Cohen J et al.. “Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31250894 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [280]
Mellby LD, Nyberg AP, Johansen JS et al.. “Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30106639 ↗
L3OTHERCited in: Biopsy and Histologic Diagnosis - [281]
Infante JR, Matsubayashi H, Sato N et al.. “Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17235047 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [282]
Seeber A, Zimmer K, Kocher F et al.. “Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.” ESMO open (2020). PMID: 33229504 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [283]
Silva T, Yamazaki T, Creasy JM et al.. “The Differential Impact of Neoadjuvant Therapies on the Tumor Microenvironment, Peripheral Biomarkers, and Survival in Pancreatic Cancer: A Retrospective Cohort Study.” Cancers (2026). PMID: 42192927 ↗
L2COHORTCited in: Biopsy and Histologic Diagnosis - [284]
Li K, Tandurella JA, Gai J et al.. “Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy.” Cancer cell (2022). PMID: 36306792 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Management Overview - [285]
Jena A, Dhar J, Dell'Anna G et al.. “Endoscopic Ultrasound fine-needle aspiration and cystic fluid analysis in patients with pancreatic cystic lesions.” Best practice & research. Clinical gastroenterology (2026). PMID: 42167855 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [286]
Carrara S, Bevere M, Delle Cave D et al.. “Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41866258 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [287]
Yao G, Zhang Y, Li H et al.. “Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.” Clinical and translational gastroenterology (2026). PMID: 41718013 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [288]
Hussain MM, Qammar S, Wang JM et al.. “Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers.” Journal of gastroenterology and hepatology (2026). PMID: 41692706 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [289]
Pimenova M, Rosenbaum MW. “Cytology and small biopsy diagnosis of pancreatic ductal adenocarcinoma.” Seminars in diagnostic pathology (2026). PMID: 41653565 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [290]
Wang L, Chen Z, He X et al.. “Research progress on early diagnostic markers for pancreatic cancer.” World journal of surgical oncology (2026). PMID: 41588412 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [291]
Sharma SK, Mack KN, Piersigilli A et al.. “ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34907079 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [292]
Khorana AA, Ahrendt SA, Ryan CK et al.. “Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17504985 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [293]
Strouch MJ, Cheon EC, Salabat MR et al.. “Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20371681 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [294]
Gao C, Wisniewski L, Liu Y et al.. “Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33093149 ↗
L3OTHERCited in: Biopsy and Histologic Diagnosis - [295]
Collisson EA. “Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32661068 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis - [296]
Kim H, Saka B, Knight S et al.. “Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24486587 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [297]
Michaels AD, Newhook TE, Adair SJ et al.. “CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 29288236 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis, Staging - [298]
Bausch D, Thomas S, Mino-Kenudson M et al.. “Plectin-1 as a novel biomarker for pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 21098698 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [299]
Ni C, Xu J, Pang Y et al.. “Case Report: Converting an immunologically "cold" tumor: exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma.” Frontiers in immunology (2026). PMID: 42358962 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Management Overview - [300]
Ramanathan RK, Goldstein D, Korn RL et al.. “Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26802153 ↗
L1RCTCited in: Imaging, Prognosis and Prognostic Factors - [301]
Wyse JM, Carone M, Paquin SC et al.. “Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21844506 ↗
L1RCTCited in: Imaging - [302]
Picozzi V, Alseidi A, Winter J et al.. “Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.” ESMO open (2020). PMID: 32817130 ↗
L2RCTCited in: Imaging, Special Populations - [303]
Ko AH, Dito E, Schillinger B et al.. “Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005). PMID: 16344320 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [304]
Von Hoff DD, Ramanathan RK, Borad MJ et al.. “Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21969517 ↗
L2TRIAL_NONRANDOMCited in: Imaging - [305]
Heinrich S, Pestalozzi BC, Schäfer M et al.. “Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18487569 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [306]
Conroy T, Castan F, Lopez A et al.. “Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.” JAMA oncology (2022). PMID: 36048453 ↗
L1RCTCited in: Imaging, Management Overview - [307]
Murthy P, Zenati MS, AlMasri SS et al.. “Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38150819 ↗
L3OTHERCited in: Imaging, Management Overview - [308]
Martin RCG, Scheon E, Govindarajan N et al.. “pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer.” Pancreas (2026). PMID: 41941588 ↗
L1GUIDELINECited in: Imaging, Prognosis and Prognostic Factors - [309]
Lohrmann C, O'Reilly EM, O'Donoghue JA et al.. “Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31540979 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [310]
Memon M, Chatzielefthreiou E, Kowal MR et al.. “The impact of MRI on real-world staging pathways and management timelines in pancreatic cancer: A systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41996777 ↗
L1SR_OBSCited in: Imaging, Staging, Prognosis and Prognostic Factors - [311]
Stefanidis D, Grove KD, Schwesinger WH et al.. “The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16236756 ↗
L5REVIEW_NARRATIVECited in: Imaging, Staging, Prognosis and Prognostic Factors - [312]
Humphris JL, Chang DK, Johns AL et al.. “The prognostic and predictive value of serum CA19.9 in pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22241899 ↗
L3OTHERCited in: Imaging, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [313]
Ramanathan RK, Korn RL, Chiorean EG et al.. “Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27240995 ↗
L5OTHERCited in: Imaging - [314]
Verslype C, Van Cutsem E, Dicato M et al.. “The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17600091 ↗
L5OTHERCited in: Imaging, Staging - [315]
Hajj C, Goodman KA. “Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918298 ↗
L5REVIEW_NARRATIVECited in: Imaging, Molecular Diagnostics and Biomarkers - [316]
Dekker EN, van Dam JL, Janssen QP et al.. “Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38315954 ↗
L3OTHERCited in: Imaging - [317]
Vasen H, Ibrahim I, Ponce CG et al.. “Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27114589 ↗
L2OTHERCited in: Imaging - [318]
Pedrazzoli S. “Extent of lymphadenectomy to associate with pancreaticoduodenectomy in patients with pancreatic head cancer for better tumor staging.” Cancer treatment reviews (2015). PMID: 26045226 ↗
L5REVIEW_NARRATIVECited in: Imaging, Staging - [319]
Alves N, Schuurmans M, Rutkowski D et al.. “Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study.” The Lancet. Oncology (2025). PMID: 41275871 ↗
L2OTHERCited in: Imaging, Special Populations - [320]
Schmitz D, Yazdi F, Claaßen K et al.. “Prevalence and natural course of MRI-diagnosed dilated main pancreatic duct: A longitudinal, population-based prospective cohort study with a ten-year follow-up.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41927409 ↗
L2COHORTCited in: Imaging - [321]
Gupta M, Choi H, Kemp SB et al.. “Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40260640 ↗
L4OTHERCited in: Imaging - [322]
Asano H, Elhelaly AE, Hyodo F et al.. “Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37732903 ↗
L4OTHERCited in: Imaging - [323]
Payen T, Oberstein PE, Saharkhiz N et al.. “Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31831559 ↗
L4OTHERCited in: Imaging, Staging - [324]
Heid I, Steiger K, Trajkovic-Arsic M et al.. “Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27663591 ↗
L4OTHERCited in: Imaging - [325]
Kato S, Adashek JJ, Shaya J et al.. “Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33472910 ↗
L4OTHERCited in: Imaging, Staging - [326]
Henry KE, Dacek MM, Dilling TR et al.. “A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30228208 ↗
L5OTHERCited in: Imaging - [327]
Moroz A, Wang YH, Sharib JM et al.. “Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32341034 ↗
L5OTHERCited in: Imaging - [328]
Tan BH, Birdsell LA, Martin L et al.. “Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19887488 ↗
L2OTHERCited in: Imaging - [329]
Potjer TP, Schot I, Langer P et al.. “Variation in precursor lesions of pancreatic cancer among high-risk groups.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23172884 ↗
L2OTHERCited in: Imaging - [330]
Henke LE, Kim H, Laugeman E et al.. “Stereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial.” JMIR research protocols (2026). PMID: 41730182 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [331]
Gherghescu CG, Baz RA, Dina C et al.. “Serum Biomarkers and CT-Derived Muscle Indices in Sarcopenia Associated with Pancreatic Neoplasm: A Comparative Clinical Study.” Chirurgia (Bucharest, Romania : 1990) (2026). PMID: 42084250 ↗
L1RCTCited in: Imaging - [332]
Duggal S, Kalas M, Eldesouki MH et al.. “Role of Endoscopic Ultrasonography in Management of Pancreaticobiliary Cancers: Recent Trends and Advances.” Cancers (2026). PMID: 42352399 ↗
L5REVIEW_NARRATIVECited in: Imaging - [333]
Tsai CJ, Lin PY, Ong KH et al.. “Evaluating the prognostic significance of lymph node yield in resected pancreatic adenocarcinoma: a population-based study.” World journal of surgical oncology (2026). PMID: 42343361 ↗
L2OTHERCited in: Imaging - [334]
Yamaguchi T, Sofue K, Masuda A et al.. “Deep Learning Detection of Direct and Indirect Imaging Findings Associated with Pancreatic Cancer at Contrast-enhanced and Noncontrast CT.” Radiology (2026). PMID: 42301012 ↗
L3OTHERCited in: Imaging - [335]
Wu C, Tian B, Yang J. “A Naples prognostic score-based nomogram enhances perioperative risk stratification for resected pancreatic cancer.” Future oncology (London, England) (2026). PMID: 42287173 ↗
L3OTHERCited in: Imaging - [336]
Eder AC, Wielenberg CF, Omrane MA et al.. “First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [68Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findings.” European journal of nuclear medicine and molecular imaging (2026). PMID: 42268404 ↗
L4OTHERCited in: Imaging - [337]
Bidard FC, Huguet F, Louvet C et al.. “Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23676420 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [338]
Fuchs CS, Azevedo S, Okusaka T et al.. “A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25609246 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [339]
Chiorean EG, Von Hoff DD, Reni M et al.. “CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26802160 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [340]
Deplanque G, Demarchi M, Hebbar M et al.. “A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25858497 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [341]
Knox JJ, O'Kane G, King D et al.. “PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40929627 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations - [342]
Macarulla T, Pazo-Cid R, Guillén-Ponce C et al.. “Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30523758 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [343]
Liu JF, Moore KN, Birrer MJ et al.. “Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27793850 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers - [344]
Hartlapp I, Valta-Seufzer D, Siveke JT et al.. “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).” ESMO open (2022). PMID: 35970013 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [345]
Scarlato E, Merz V, Pietrobono S et al.. “Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.” ESMO open (2026). PMID: 42090751 ↗
L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Special Populations - [346]
Christensen TD, Maag E, Theile S et al.. “Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma.” ESMO open (2024). PMID: 38838501 ↗
L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [347]
Hess V, Glimelius B, Grawe P et al.. “CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.” The Lancet. Oncology (2008). PMID: 18249033 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [348]
Huffman BM, Diossy M, Yurgelun MB et al.. “A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41686836 ↗
L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [349]
Tempero MA. “NCCN Guidelines Updates: Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117041 ↗
L1OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [350]
San Lucas FA, Allenson K, Bernard V et al.. “Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26681674 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers - [351]
Yin L, Cao C, Lin J et al.. “Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40311105 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [352]
Lee CJ, Dosch J, Simeone DM. “Pancreatic cancer stem cells.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18539958 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [353]
Ko AH. “Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918299 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [354]
Brozos-Vázquez E, Toledano-Fonseca M, Costa-Fraga N et al.. “Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.” Cancer treatment reviews (2024). PMID: 38490088 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview - [355]
Jones L, Cunningham D, Starling N. “HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.” Cancer treatment reviews (2024). PMID: 38959629 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview - [356]
El Maalouf G, Le Tourneau C, Batty GN et al.. “Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.” Cancer treatment reviews (2008). PMID: 19027240 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [357]
Nishizaki D, Kurzrock R, Miyashita H et al.. “Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.” ESMO open (2024). PMID: 38503143 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations - [358]
Jordheim LP, Sève P, Trédan O et al.. “The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.” The Lancet. Oncology (2010). PMID: 21163702 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [359]
Mariussi M, Lima LCO, Ruelas MG et al.. “Irreversible electroporation combined with immunotherapy versus irreversible electroporation alone for locally advanced pancreatic cancer: a systematic review and meta-analysis.” Einstein (Sao Paulo, Brazil) (2026). PMID: 42054172 ↗
L1SR_OBSCited in: Molecular Diagnostics and Biomarkers - [360]
Valero C, Lee M, Hoen D et al.. “Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.” JAMA oncology (2021). PMID: 33599686 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [361]
Maddipati R, Stanger BZ. “Pancreatic Cancer Metastases Harbor Evidence of Polyclonality.” Cancer discovery (2015). PMID: 26209539 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [362]
Schram AM, Odintsov I, Espinosa-Cotton M et al.. “Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.” Cancer discovery (2022). PMID: 35135829 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [363]
. “Targeting Macrophages Boosts Pancreatic Cancer Therapy.” Cancer discovery (2016). PMID: 27170064 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [364]
Huang YH, Hu J, Chen F et al.. “ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer.” Cancer discovery (2019). PMID: 31582374 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [365]
Hobbs GA, Baker NM, Miermont AM et al.. “Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.” Cancer discovery (2019). PMID: 31649109 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [366]
Kothari V, Wei I, Shankar S et al.. “Outlier kinase expression by RNA sequencing as targets for precision therapy.” Cancer discovery (2013). PMID: 23384775 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [367]
Wang Y, Lih TM, Lee JW et al.. “Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct patterns and potential markers of progression.” Cancer cell (2025). PMID: 40882635 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations - [368]
Shukla SK, Purohit V, Mehla K et al.. “MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.” Cancer cell (2017). PMID: 28697344 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [369]
Singh H, Xiu J, Kapner KS et al.. “Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39283131 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations - [370]
Ozawa H, Takahashi K, Motegi T et al.. “Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 41086055 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [371]
Van Cutsem E, Collignon J, Eefsen RL et al.. “Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39385434 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [372]
Carpenter ES, Kadiyala P, Elhossiny AM et al.. “KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 37851080 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [373]
Yamamoto N, Dobersch S, Loveless I et al.. “HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680021 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [374]
Oberg AL, Bamlet WR, Izmirlian G et al.. “Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41870276 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [375]
Yamamoto K, Iwase A, Maeda H. “Tumor-Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development.” Clinical and translational science (2026). PMID: 42257532 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [376]
Takrori E, Abdulmajid M, Devagudi D et al.. “Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy.” International journal of molecular sciences (2026). PMID: 42196390 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [377]
Bao W, Leng K, Xia X et al.. “Integrating single-cell analysis and digital pathology for risk stratification in pancreatic cancer.” Clinical & experimental metastasis (2026). PMID: 42189258 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers - [378]
Jung H, Park N, Kim J et al.. “Mass Spectrometry-Driven Proteomic Biomarkers for Serum-Based Detection of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm-Associated Invasive Carcinoma.” Cancer medicine (2026). PMID: 42136141 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers - [379]
Lee J, Zhu Y, Tseng HR. “Bioorthogonal Click Chemistry-Enabled Enrichment of Extracellular Vesicles for Integrated Molecular and Functional Liquid Biopsy§.” Accounts of chemical research (2026). PMID: 42134309 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [380]
Sun W, Wang Y, Qiao X et al.. “Multiomics and Genomic Alteration Characterization Identifies VDAC1 as a Mitochondrial-Associated Biomarker in Pancreatic Cancer.” Human mutation (2026). PMID: 42111501 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers - [381]
Hong W. “Role of cancer-associated fibroblast-derived exosomes in pancreatic cancer: clinical therapeutic potential and targeting challenges.” Frontiers in immunology (2026). PMID: 42099594 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [382]
Bendell J, O'Reilly EM, Middleton MR et al.. “Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25573533 ↗
L1RCTCited in: Staging - [383]
Löhr JM, Haas SL, Bechstein WO et al.. “Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21896540 ↗
L1RCTCited in: Staging - [384]
Evans TRJ, Van Cutsem E, Moore MJ et al.. “Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998964 ↗
L1RCTCited in: Staging - [385]
Boeck S, Hoehler T, Seipelt G et al.. “Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17962204 ↗
L1RCTCited in: Staging - [386]
Cunningham D, Chau I, Stocken DD et al.. “Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858379 ↗
L1RCTCited in: Staging - [387]
Hurwitz HI, Uppal N, Wagner SA et al.. “Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26351344 ↗
L1RCTCited in: Staging - [388]
Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al.. “Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23213101 ↗
L1RCTCited in: Staging - [389]
Kulke MH, Tempero MA, Niedzwiecki D et al.. “Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858396 ↗
L1RCTCited in: Staging - [390]
Catenacci DV, Junttila MR, Karrison T et al.. “Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26527777 ↗
L1RCTCited in: Staging - [391]
Herman JM, Wild AT, Wang H et al.. “Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23341531 ↗
L1RCTCited in: Staging - [392]
Borad MJ, Reddy SG, Bahary N et al.. “Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25512461 ↗
L1RCTCited in: Staging - [393]
Schorn S, Demir IE, Reyes CM et al.. “The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.” Cancer treatment reviews (2017). PMID: 28342938 ↗
L1SR_OBSCited in: Staging - [394]
Meti N, Kelly D, Allen MJ et al.. “Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies.” Cancer treatment reviews (2021). PMID: 34757307 ↗
L1SR_OBSCited in: Staging, Prognosis and Prognostic Factors - [395]
Du L, Wang-Gillam A. “Trends in Neoadjuvant Approaches in Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784867 ↗
L5REVIEW_NARRATIVECited in: Staging, Management Overview, Prognosis and Prognostic Factors - [396]
Lee J, Park SH, Chang HM et al.. “Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.” The Lancet. Oncology (2011). PMID: 22192731 ↗
L1RCTCited in: Staging, Special Populations - [397]
Kordes S, Pollak MN, Zwinderman AH et al.. “Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26067687 ↗
L1RCTCited in: Staging, Special Populations - [398]
Starling N, Watkins D, Cunningham D et al.. “Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858399 ↗
L2TRIAL_NONRANDOMCited in: Staging - [399]
Evans DB, Varadhachary GR, Crane CH et al.. “Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18640930 ↗
L2TRIAL_NONRANDOMCited in: Staging - [400]
Nywening TM, Wang-Gillam A, Sanford DE et al.. “Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.” The Lancet. Oncology (2016). PMID: 27055731 ↗
L2TRIAL_NONRANDOMCited in: Staging - [401]
Rivera F, López-Tarruella S, Vega-Villegas ME et al.. “Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.” Cancer treatment reviews (2009). PMID: 19131170 ↗
L5REVIEW_NARRATIVECited in: Staging - [402]
Du SQ, Liu YT, Yang F et al.. “Potential correlation between high SNHG expression and poor pancreatic cancer prognosis: evidence from systematic reviews and meta-analyses.” Cancer cell international (2026). PMID: 41654901 ↗
L1SR_OBSCited in: Staging - [403]
D'Ambra V, Ricci C, Ingaldi C et al.. “Predictive factors for long-term survival in pancreatic ductal adenocarcinoma that underwent surgery: a systematic review and meta-analysis of literature.” Updates in surgery (2025). PMID: 40889102 ↗
L1SR_OBSCited in: Staging - [404]
Ungureanu BS, Gheonea DI, Turcu-Stiolica A et al.. “Clinicopathologic relevance of EpCAM and CD44 in pancreatic cancer: insights from a meta-analysis.” Stem cell research & therapy (2025). PMID: 40866982 ↗
L1SR_OBSCited in: Staging - [405]
Salcedo-Allende MT, Fuste Chimisana V, Zucchiatti Llanos AC et al.. “Position statement on the pathological assessment of pancreatic resection specimens in pancreatic ductal adenocarcinoma by the Societat Catalana de Pàncrees and the Societat Catalana d'Anatomia Patològica.” Gastroenterologia y hepatologia (2026). PMID: 41655901 ↗
L1GUIDELINECited in: Staging - [406]
Kruger S, Heinemann V, Ross C et al.. “Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30346475 ↗
L2OTHERCited in: Staging - [407]
Heinemann V. “Treatment of locoregional disease: adjuvant versus neoadjuvant.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22987951 ↗
L5OTHERCited in: Staging - [408]
Malvezzi M, Bertuccio P, Rosso T et al.. “European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25623049 ↗
L2OTHERCited in: Staging - [409]
Costa ACD, Duarte VA, Santa Cruz F et al.. “Pancreatoduodenectomy with vascular reconstruction versus chemotherapy alone in patients with locally advanced pancreatic cancer: a systematic review.” Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery (2025). PMID: 40767666 ↗
L2SR_OBSCited in: Staging - [410]
Li H, Mo Z, Tong G. “Value of CRP, albumin, and lymphocyte index in predicting survival of patients with gastrointestinal malignancies: a systematic review and meta-analysis.” Frontiers in oncology (2025). PMID: 40740873 ↗
L1SR_OBSCited in: Staging - [411]
Chang DK, Johns AL, Merrett ND et al.. “Margin clearance and outcome in resected pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19398572 ↗
L2OTHERCited in: Staging - [412]
Mokdad AA, Minter RM, Zhu H et al.. “Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27621388 ↗
L2OTHERCited in: Staging - [413]
Borsati A, Toniolo L, Adamoli G et al.. “Structured Exercise During Chemotherapy for Locally Advanced or Metastatic Pancreatic Cancer: A Single-Arm, Feasibility Trial.” Cancer medicine (2026). PMID: 41700007 ↗
L4TRIAL_NONRANDOMCited in: Staging - [414]
Batist G, Kavan P, Augustin L et al.. “A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer.” Cancer immunology, immunotherapy : CII (2026). PMID: 41591505 ↗
L3TRIAL_NONRANDOMCited in: Staging - [415]
Hong J, Kohutek ZA, Zhang H et al.. “Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer.” Cancer discovery (2026). PMID: 41650466 ↗
L2OTHERCited in: Staging, Prognosis and Prognostic Factors - [416]
Wartenberg M, Cibin S, Zlobec I et al.. “Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29661773 ↗
L2OTHERCited in: Staging - [417]
Shi M, Cui J, Du J et al.. “A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24947925 ↗
L4OTHERCited in: Staging - [418]
Huang C, Li Y, Li Z et al.. “LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30679163 ↗
L4OTHERCited in: Staging - [419]
Nixon AB, Pang H, Starr MD et al.. “Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24097873 ↗
L2OTHERCited in: Staging - [420]
Pietrasz D, Pécuchet N, Garlan F et al.. “Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27993964 ↗
L2OTHERCited in: Staging - [421]
Philip PA, Chansky K, LeBlanc M et al.. “Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24914040 ↗
L2OTHERCited in: Staging - [422]
Cloyd JM, Colby S, Guthrie KA et al.. “Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38688309 ↗
L1RCTCited in: Management Overview, Special Populations - [423]
Van Laethem JL, Verslype C, Iovanna JL et al.. “New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21810728 ↗
L1GUIDELINECited in: Management Overview - [424]
Seufferlein T, Uhl W, Kornmann M et al.. “Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 36209981 ↗
L1RCTCited in: Management Overview - [425]
Versteijne E, van Dam JL, Suker M et al.. “Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35084987 ↗
L1RCTCited in: Management Overview - [426]
Versteijne E, Suker M, Groothuis K et al.. “Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32105518 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [427]
Kindler HL, Hammel P, Reni M et al.. “Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35834777 ↗
L1RCTCited in: Management Overview - [428]
Ohba A, Ozaka M, Mizusawa J et al.. “Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40720715 ↗
L1RCTCited in: Management Overview, Special Populations - [429]
Ducreux M, Desgrippes R, Rinaldi Y et al.. “PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40378359 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [430]
Oettle H, Riess H, Stieler JM et al.. “Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24982456 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [431]
Ueno H, Ioka T, Ikeda M et al.. “Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23547081 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [432]
Fietkau R, Ghadimi M, Grützmann R et al.. “Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40802908 ↗
L1RCTCited in: Management Overview, Special Populations - [433]
Conroy T, Ducreux M. “ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer.” ESMO open (2025). PMID: 40287191 ↗
L1GUIDELINECited in: Management Overview - [434]
Farge D, Frere C, Connors JM et al.. “2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.” The Lancet. Oncology (2022). PMID: 35772465 ↗
L1GUIDELINECited in: Management Overview - [435]
Uson Junior PLS, Dias E Silva D, de Castro NM et al.. “Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.” ESMO open (2023). PMID: 36638709 ↗
L1SR_MA_RCTCited in: Management Overview - [436]
Chow R, Lage DE, Williams GR et al.. “Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 34991068 ↗
L5SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [437]
Janssen QP, van Dam JL, van Bekkum ML et al.. “Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.” The Lancet. Oncology (2025). PMID: 40945523 ↗
L1RCTCited in: Management Overview, Special Populations - [438]
Reiss KA, Mick R, Teitelbaum U et al.. “Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.” The Lancet. Oncology (2022). PMID: 35810751 ↗
L1RCTCited in: Management Overview - [439]
Taniguchi CM, Frakes JM, Aguilera TA et al.. “Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.” The Lancet. Oncology (2023). PMID: 38039992 ↗
L1RCTCited in: Management Overview, Special Populations - [440]
Conroy T, Desseigne F, Ychou M et al.. “FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.” The New England journal of medicine (2011). PMID: 21561347 ↗
L1RCTCited in: Management Overview, Special Populations - [441]
Von Hoff DD, Ervin T, Arena FP et al.. “Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.” The New England journal of medicine (2013). PMID: 24131140 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [442]
Guillevin L, Pagnoux C, Karras A et al.. “Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.” The New England journal of medicine (2014). PMID: 25372085 ↗
L1RCTCited in: Management Overview, Special Populations - [443]
Green JB, Bethel MA, Armstrong PW et al.. “Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2015). PMID: 26052984 ↗
L1RCTCited in: Management Overview - [444]
Bai X, Li X, Chen Y et al.. “Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial.” Cancer cell (2025). PMID: 41072417 ↗
L1RCTCited in: Management Overview, Special Populations - [445]
Mastrantoni L, Chiaravalli M, Spring A et al.. “Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.” The Lancet. Oncology (2024). PMID: 39542008 ↗
L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors - [446]
Rahib L, Fleshman JM, Matrisian LM et al.. “Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.” JAMA oncology (2016). PMID: 27270617 ↗
L1TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors - [447]
Kaufman B, Shapira-Frommer R, Schmutzler RK et al.. “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25366685 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [448]
Qi C, Zhang P, Liu C et al.. “Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38788174 ↗
L4TRIAL_NONRANDOMCited in: Management Overview - [449]
Pijnappel EN, Suurmeijer JA, Koerkamp BG et al.. “Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.” JAMA oncology (2022). PMID: 35446336 ↗
L5SR_OBSCited in: Management Overview - [450]
Ruan DY, Liu FR, Wei XL et al.. “Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.” The Lancet. Oncology (2025). PMID: 39788133 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations - [451]
Musher BL, Rowinsky EK, Smaglo BG et al.. “LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.” The Lancet. Oncology (2024). PMID: 38547893 ↗
L4TRIAL_NONRANDOMCited in: Management Overview - [452]
Wolpin BM, Park W, Garrido-Laguna I et al.. “Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.” The New England journal of medicine (2026). PMID: 42090791 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [453]
Strickler JH, Satake H, George TJ et al.. “Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.” The New England journal of medicine (2022). PMID: 36546651 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors - [454]
Brahmer JR, Tykodi SS, Chow LQ et al.. “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.” The New England journal of medicine (2012). PMID: 22658128 ↗
L4TRIAL_NONRANDOMCited in: Management Overview - [455]
Ghanem I, Lora D, Herradón N et al.. “Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.” ESMO open (2022). PMID: 35580504 ↗
L1SR_OBSCited in: Management Overview - [456]
Herman JM, Hoffman JP, Thayer SP et al.. “Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26158133 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors - [457]
Rosso C, Marciano ND, Nathan D et al.. “Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38889755 ↗
L3OTHERCited in: Management Overview, Special Populations - [458]
Chua YJ, Zalcberg JR. “Pancreatic cancer--is the wall crumbling?” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18381371 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [459]
Mateo J, Lord CJ, Serra V et al.. “A decade of clinical development of PARP inhibitors in perspective.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31218365 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [460]
Tempero MA, Berlin J, Ducreux M et al.. “Pancreatic cancer treatment and research: an international expert panel discussion.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21199884 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [461]
Taieb J, Pointet AL, Van Laethem JL et al.. “What treatment in 2017 for inoperable pancreatic cancers?” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28459988 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors - [462]
Sahin IH, Askan G, Hu ZI et al.. “Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28945842 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [463]
Heinemann V, Haas M, Boeck S. “Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23852311 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors - [464]
Adjei AA. “Clinical studies of pemetrexed and gemcitabine combinations.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16807459 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [465]
Shindo K, Yu J, Suenaga M et al.. “Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28767289 ↗
L3OTHERCited in: Management Overview - [466]
Szymczak-Pajor I, Drzewoski J, Wenclewska S et al.. “Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?” International journal of molecular sciences (2026). PMID: 42196179 ↗
L1SR_OBSCited in: Management Overview - [467]
Henriksen A, Dyhl-Polk A, Chen I et al.. “Checkpoint inhibitors in pancreatic cancer.” Cancer treatment reviews (2019). PMID: 31325788 ↗
L2REVIEW_NARRATIVECited in: Management Overview - [468]
van Kampen JG, Marijnissen-van Zanten MA, Simmer F et al.. “Epigenetic targeting in pancreatic cancer.” Cancer treatment reviews (2014). PMID: 24433955 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors - [469]
Lai E, Puzzoni M, Ziranu P et al.. “New therapeutic targets in pancreatic cancer.” Cancer treatment reviews (2019). PMID: 31739115 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [470]
Schizas D, Charalampakis N, Kole C et al.. “Immunotherapy for pancreatic cancer: A 2020 update.” Cancer treatment reviews (2020). PMID: 32247999 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [471]
Belli C, Cereda S, Anand S et al.. “Neoadjuvant therapy in resectable pancreatic cancer: a critical review.” Cancer treatment reviews (2012). PMID: 23122322 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [472]
Oehler C, Ciernik IF. “Radiation therapy and combined modality treatment of gastrointestinal carcinomas.” Cancer treatment reviews (2006). PMID: 16524667 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors - [473]
Heinemann V, Haas M, Boeck S. “Systemic treatment of advanced pancreatic cancer.” Cancer treatment reviews (2012). PMID: 22226241 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [474]
Dusetti N, Bachet JB, Chanez B et al.. “Medical management of pancreatic cancer: from personalization to broadening treatment strategies.” Cancer treatment reviews (2025). PMID: 40466554 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [475]
Catanese S, Pentheroudakis G, Douillard JY et al.. “ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.” ESMO open (2020). PMID: 32423899 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [476]
Roeyen G, Berrevoet F, Borbath I et al.. “Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer.” ESMO open (2022). PMID: 35124465 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [477]
Webb N, Fricke J, Hancock E et al.. “The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology.” ESMO open (2020). PMID: 32576610 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [478]
Koessler T, Alsina M, Arnold D et al.. “ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.” ESMO open (2022). PMID: 35180656 ↗
L5OTHERCited in: Management Overview - [479]
Leidner R, Sanjuan Silva N, Huang H et al.. “Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.” The New England journal of medicine (2022). PMID: 35648703 ↗
L4OTHERCited in: Management Overview - [480]
Canavan ME, Wang X, Ascha MS et al.. “Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors.” JAMA oncology (2024). PMID: 38753341 ↗
L2OTHERCited in: Management Overview - [481]
Dilly J, Hoffman MT, Abbassi L et al.. “Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.” Cancer discovery (2024). PMID: 38975874 ↗
L4OTHERCited in: Management Overview - [482]
Dominguez CX, Müller S, Keerthivasan S et al.. “Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.” Cancer discovery (2019). PMID: 31699795 ↗
L5OTHERCited in: Management Overview, Prognosis and Prognostic Factors - [483]
Tiriac H, Belleau P, Engle DD et al.. “Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.” Cancer discovery (2018). PMID: 29853643 ↗
L4OTHERCited in: Management Overview - [484]
Singhal A, Styers HC, Rub J et al.. “A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer.” Cancer discovery (2024). PMID: 38975873 ↗
L5OTHERCited in: Management Overview - [485]
Kemp SB, Cheng N, Markosyan N et al.. “Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.” Cancer discovery (2023). PMID: 36472553 ↗
L5OTHERCited in: Management Overview - [486]
Belle JI, Sen D, Baer JM et al.. “Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer.” Cancer discovery (2024). PMID: 38683144 ↗
L5OTHERCited in: Management Overview - [487]
Bianchi A, De Castro Silva I, Deshpande NU et al.. “Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.” Cancer discovery (2023). PMID: 36946782 ↗
L5OTHERCited in: Management Overview - [488]
McAndrews KM, Chen Y, Darpolor JK et al.. “Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.” Cancer discovery (2022). PMID: 35348629 ↗
L5OTHERCited in: Management Overview - [489]
Yamaguchi N, Wu YG, Ravetch E et al.. “A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1α Nuclear Retention.” Cancer discovery (2024). PMID: 39028915 ↗
L5OTHERCited in: Management Overview - [490]
Schalck A, Sakellariou-Thompson D, Forget MA et al.. “Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.” Cancer discovery (2022). PMID: 35849783 ↗
L4OTHERCited in: Management Overview - [491]
Yuan L, Ji W, Dwyer BG et al.. “Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex.” Cancer discovery (2025). PMID: 40891634 ↗
L5OTHERCited in: Management Overview - [492]
. “Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.” Cancer discovery (2022). PMID: 35373275 ↗
L5OTHERCited in: Management Overview - [493]
Ravichandran M, Hu J, Cai C et al.. “Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer.” Cancer discovery (2022). PMID: 35771494 ↗
L5OTHERCited in: Management Overview - [494]
Renz BW, Takahashi R, Tanaka T et al.. “β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.” Cancer cell (2017). PMID: 29249692 ↗
L5OTHERCited in: Management Overview - [495]
Mucciolo G, Araos Henríquez J, Jihad M et al.. “EGFR-activated myofibroblasts promote metastasis of pancreatic cancer.” Cancer cell (2023). PMID: 38157863 ↗
L5OTHERCited in: Management Overview - [496]
Bear AS, Vonderheide RH, O'Hara MH. “Challenges and Opportunities for Pancreatic Cancer Immunotherapy.” Cancer cell (2020). PMID: 32946773 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [497]
Mahadevan KK, McAndrews KM, LeBleu VS et al.. “KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells.” Cancer cell (2023). PMID: 37625401 ↗
L5OTHERCited in: Management Overview - [498]
Riedl JM, Matsubara H, McNeil R et al.. “Emerging landscape of KRAS inhibitors in cancer treatment.” Cancer cell (2026). PMID: 41616774 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [499]
Liu X, Hogg GD, Zuo C et al.. “Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity.” Cancer cell (2023). PMID: 37236195 ↗
L5OTHERCited in: Management Overview - [500]
Gabitova-Cornell L, Surumbayeva A, Peri S et al.. “Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.” Cancer cell (2020). PMID: 32976774 ↗
L5OTHERCited in: Management Overview - [501]
Du H, Hirabayashi K, Ahn S et al.. “Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.” Cancer cell (2019). PMID: 30753824 ↗
L5OTHERCited in: Management Overview - [502]
Piper M, Hoen M, Darragh LB et al.. “Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.” Cancer cell (2023). PMID: 37116489 ↗
L5OTHERCited in: Management Overview - [503]
Wei D, Wang L, Zuo X et al.. “A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 37831007 ↗
L5OTHERCited in: Management Overview - [504]
Wehrli M, Guinn S, Birocchi F et al.. “Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38393682 ↗
L5OTHERCited in: Management Overview - [505]
McVey JC, Beatty GL. “Facts and Hopes of CD40 Agonists in Cancer Immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40117130 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [506]
O'Kane GM, Grünwald BT, Jang GH et al.. “GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32156747 ↗
L2OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [507]
Wang S, Yu G, Dai Y et al.. “IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40586688 ↗
L5OTHERCited in: Management Overview - [508]
Singh H, Keller RB, Kapner KS et al.. “Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37463056 ↗
L4OTHERCited in: Management Overview - [509]
Grossman JE, Muthuswamy L, Huang L et al.. “Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34789479 ↗
L2OTHERCited in: Management Overview - [510]
Steele NG, Biffi G, Kemp SB et al.. “Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33495315 ↗
L5OTHERCited in: Management Overview - [511]
Cornwell AC, Tisdale AA, Venkat S et al.. “Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37587561 ↗
L4OTHERCited in: Management Overview - [512]
Manji GA, Olive KP, Saenger YM et al.. “Current and Emerging Therapies in Metastatic Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28373365 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [513]
Korc M. “Heparin Prowess: Favorable Vascular-Immune Reprogramming in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37099035 ↗
L5OTHERCited in: Management Overview - [514]
Richter A, Heidenhain C. “Robotic portomesenteric vein reconstruction using self-fashioned bovine pericardial grafts during Da Vinci-assisted pancreatectomy: a case series with video demonstration.” Surgical endoscopy (2026). PMID: 42257970 ↗
L4CASE_REPORTCited in: Management Overview - [515]
Schmiechen ZC, Cruz-Hinojoza E, Hilk AL et al.. “Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer.” Science immunology (2026). PMID: 42361199 ↗
L5OTHERCited in: Management Overview - [516]
Wei Z, Liu X, Zhang Z et al.. “Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy.” Oncology research (2026). PMID: 42358845 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [517]
Kuramochi T, Itaya T, Sano M et al.. “High-Dose Tramadol Enhances the Proliferative and Invasive Potential of Pancreatic Ductal Adenocarcinoma in Mice Through Microenvironmental Alteration.” Pain research & management (2026). PMID: 42325112 ↗
L5OTHERCited in: Management Overview - [518]
Dickey EM, Marsh HM, Rydberg-Millrud C et al.. “IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancer.” JCI insight (2026). PMID: 42325091 ↗
L5OTHERCited in: Management Overview - [519]
Cao Z, Qiu J, Luo W et al.. “Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study.” Signal transduction and targeted therapy (2026). PMID: 42324245 ↗
L4TRIAL_NONRANDOMCited in: Management Overview - [520]
Li F, Fu J, Lin X et al.. “Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer.” Oncology reports (2026). PMID: 42318966 ↗
L5OTHERCited in: Management Overview - [521]
Bincoletto V, Andreana I, Stella B et al.. “Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer.” Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology (2026). PMID: 42312894 ↗
L5REVIEW_NARRATIVECited in: Management Overview - [522]
Hammel P, Kindler HL, Reni M et al.. “Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31562758 ↗
L1RCTCited in: Prognosis and Prognostic Factors - [523]
Karasic TB, O'Hara MH, Loaiza-Bonilla A et al.. “Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.” JAMA oncology (2019). PMID: 31120501 ↗
L1RCTCited in: Prognosis and Prognostic Factors, Special Populations - [524]
Chung V, McDonough S, Philip PA et al.. “Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.” JAMA oncology (2017). PMID: 27978579 ↗
L1RCTCited in: Prognosis and Prognostic Factors, Special Populations - [525]
Rahma OE, Duffy A, Liewehr DJ et al.. “Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23670093 ↗
L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors - [526]
Vogel A, Ciardiello F, Hubner RA et al.. “Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.” Cancer treatment reviews (2016). PMID: 27676174 ↗
L5SR_OBSCited in: Prognosis and Prognostic Factors - [527]
Pokataev I, Fedyanin M, Polyanskaya E et al.. “Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.” ESMO open (2020). PMID: 33551067 ↗
L2SR_OBSCited in: Prognosis and Prognostic Factors - [528]
Ter Veer E, van Rijssen LB, Besselink MG et al.. “Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.” The Lancet. Oncology (2018). PMID: 29508762 ↗
L1SR_OBSCited in: Prognosis and Prognostic Factors - [529]
Weiss L, Fischer LE, Heinemann V et al.. “Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.” ESMO open (2024). PMID: 38503144 ↗
L1TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations - [530]
Murphy JE, Wo JY, Ryan DP et al.. “Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.” JAMA oncology (2019). PMID: 31145418 ↗
L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors - [531]
Lindström O, Udd M, Grönroos J et al.. “Covered self-expandable metal stents in benign biliary strictures caused by chronic pancreatitis: a randomized controlled trial of 6 versus 12 months of stenting.” Surgical endoscopy (2026). PMID: 42151467 ↗
L1RCTCited in: Prognosis and Prognostic Factors, Special Populations - [532]
Ishigaki K, Nakai Y, Kashiwabara K et al.. “Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01).” Journal of gastroenterology (2026). PMID: 41991754 ↗
L2RCTCited in: Prognosis and Prognostic Factors, Special Populations - [533]
Costamagna G, Reddy DN, Chia NH et al.. “Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial.” Annals of surgical oncology (2026). PMID: 41951900 ↗
L1RCTCited in: Prognosis and Prognostic Factors - [534]
Golan T, Sella T, Margalit O et al.. “Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993-2013.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784864 ↗
L2OTHERCited in: Prognosis and Prognostic Factors - [535]
Golan T, Javle M. “DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784866 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [536]
Hester CA, Perri G, Prakash LR et al.. “Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35948035 ↗
L2OTHERCited in: Prognosis and Prognostic Factors - [537]
Corcoran RB, Do KT, Kim JE et al.. “Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38456660 ↗
L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations - [538]
Li ZT, Sun ML, Liu FH et al.. “Prognostic Nutritional Index and Cancer Prognostic Outcomes: An Umbrella Review of Systematic Reviews and Meta-analyses of Observational Studies.” Advances in nutrition (Bethesda, Md.) (2026). PMID: 42001952 ↗
L2SR_OBSCited in: Prognosis and Prognostic Factors - [539]
Peddakota V, Chikkala B, Kottapalli MA et al.. “Short-Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-Analysis of Observational Studies.” World journal of surgery (2026). PMID: 41903157 ↗
L2SR_OBSCited in: Prognosis and Prognostic Factors - [540]
Mandalà M, Reni M, Cascinu S et al.. “Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17660490 ↗
L2OTHERCited in: Prognosis and Prognostic Factors - [541]
Uzunoglu FG, Kolbe J, Wikman H et al.. “VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23293110 ↗
L2OTHERCited in: Prognosis and Prognostic Factors - [542]
Malvezzi M, Carioli G, Bertuccio P et al.. “European cancer mortality predictions for the year 2019 with focus on breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30887043 ↗
L2OTHERCited in: Prognosis and Prognostic Factors - [543]
Kanbayashi Y, Ishikawa T, Kawachi H et al.. “Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study.” Future oncology (London, England) (2026). PMID: 41869701 ↗
L2COHORTCited in: Prognosis and Prognostic Factors - [544]
Park W, O'Connor CA, Chou JF et al.. “Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.” Nature medicine (2026). PMID: 41882405 ↗
L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors - [545]
Urman A, Ding Y, Durham J et al.. “Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.” Frontiers in immunology (2026). PMID: 41878443 ↗
L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors - [546]
Oettle H. “Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.” Cancer treatment reviews (2014). PMID: 25087471 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [547]
Gaya A, Tse V. “A preclinical and clinical review of aflibercept for the management of cancer.” Cancer treatment reviews (2012). PMID: 22264850 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [548]
Verbeke C, Löhr M, Karlsson JS et al.. “Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties.” Cancer treatment reviews (2014). PMID: 25434282 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [549]
Macchini M, Centonze F, Peretti U et al.. “Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.” Cancer treatment reviews (2022). PMID: 35184001 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [550]
Heinemann V, Reni M, Ychou M et al.. “Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.” Cancer treatment reviews (2013). PMID: 23849556 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [551]
Ahn DH, Williams TM, Goldstein DA et al.. “Adjuvant therapy for pancreas cancer in an era of value based cancer care.” Cancer treatment reviews (2015). PMID: 26620819 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [552]
Kruger SF, Lohneis A, Abendroth A et al.. “Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study.” ESMO open (2022). PMID: 35121522 ↗
L3OTHERCited in: Prognosis and Prognostic Factors - [553]
Hartwig W, Werner J, Jäger D et al.. “Improvement of surgical results for pancreatic cancer.” The Lancet. Oncology (2013). PMID: 24079875 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors - [554]
. “Ruxolitinib Benefits Some with Pancreatic Cancer.” Cancer discovery (2015). PMID: 26463833 ↗
L5OTHERCited in: Prognosis and Prognostic Factors - [555]
. “Pancreatic Cancer Survival Increases with Chemo Combo.” Cancer discovery (2016). PMID: 27363975 ↗
L5OTHERCited in: Prognosis and Prognostic Factors - [556]
Miyabayashi K, Baker LA, Deschênes A et al.. “Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes.” Cancer discovery (2020). PMID: 32703770 ↗
L5OTHERCited in: Prognosis and Prognostic Factors - [557]
Alam A, Levanduski E, Denz P et al.. “Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.” Cancer cell (2022). PMID: 35120601 ↗
L5OTHERCited in: Prognosis and Prognostic Factors - [558]
Steele CW, Karim SA, Leach JDG et al.. “CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.” Cancer cell (2016). PMID: 27265504 ↗
L5OTHERCited in: Prognosis and Prognostic Factors - [559]
Leung PQ, Elghonaimy EA, Elamir AM et al.. “Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40310472 ↗
L3OTHERCited in: Prognosis and Prognostic Factors, Special Populations - [560]
Cao L, Li H, Liu F et al.. “Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancreatic Cancer: A Multicenter Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40465840 ↗
L3OTHERCited in: Prognosis and Prognostic Factors - [561]
Aune D, Chan DSM, Vieira AR et al.. “Dietary fructose, carbohydrates, glycemic indices and pancreatic cancer risk: a systematic review and meta-analysis of cohort studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22539563 ↗
L2SR_OBSCited in: Special Populations - [562]
Macarulla T, Cid RP, Womack MS et al.. “NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.” ESMO open (2026). PMID: 41687160 ↗
L1RCTCited in: Special Populations - [563]
Assenat E, de la Fouchardière C, Portales F et al.. “Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.” ESMO open (2021). PMID: 34837745 ↗
L4RCTCited in: Special Populations - [564]
Mahalingam D, Saeed A, Powell SF et al.. “Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.” ESMO open (2025). PMID: 40403387 ↗
L4TRIAL_NONRANDOMCited in: Special Populations - [565]
Rossi M, Lugo A, Lagiou P et al.. “Proanthocyanidins and other flavonoids in relation to pancreatic cancer: a case-control study in Italy.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 22052986 ↗
L3CASE_CONTROLCited in: Special Populations - [566]
Mackay TM, van Rijssen LB, Andriessen JO et al.. “Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32502981 ↗
L2OTHERCited in: Special Populations - [567]
Grierson PM, Wolf C, Suresh R et al.. “Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40125795 ↗
L4TRIAL_NONRANDOMCited in: Special Populations - [568]
Macchini M, Chiaravalli M, Zanon S et al.. “Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.” Cancer treatment reviews (2018). PMID: 30414985 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [569]
Massaro M, Comito T, Franzese C et al.. “Adjuvant stereotactic pancreatic radiotherapy (SPARTA trial): interim safety analysis of an ongoing phase II single center prospective study.” Radiation oncology (London, England) (2026). PMID: 42129843 ↗
L4TRIAL_NONRANDOMCited in: Special Populations - [570]
Kanhailal AC, Knikman JE, Zielhuis SWJ et al.. “The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42114409 ↗
L4TRIAL_NONRANDOMCited in: Special Populations - [571]
Abdelrahim M, Khan G, Hatoum H et al.. “Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.” Future oncology (London, England) (2026). PMID: 42080361 ↗
L1TRIAL_NONRANDOMCited in: Special Populations - [572]
Aguirre AJ, Nowak JA, Camarda ND et al.. “Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.” Cancer discovery (2018). PMID: 29903880 ↗
L2OTHERCited in: Special Populations - [573]
Lesina M, Kurkowski MU, Ludes K et al.. “Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.” Cancer cell (2011). PMID: 21481788 ↗
L5OTHERCited in: Special Populations